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Abbreviations table 
 
Akt = Protein kinase B 
BDNF = Brain-derived neurotrophic factor 
CNS = Central nervous system 
GPCR = G protein coupled receptor 
NT-3 = Neurotrophin-3 
NT-4/5 = Neurotrophin-4/5 
NGF = Nerve growth factor 
Trk = Tropomyosin receptor kinase 
dpi = Days Post Immunization 
MS = Multiple Sclerosis 
EBV = Epstein-Barr Virus 
HSV = Herpes Simplex Virus 
Cpn = Chlamidia pneumonia 
RRMS = Relapsing Remitting Multiple Sclerosis 
SPMS = secondary progressive Multiple Sclerosis 
PPMS = Primary Progressive Multiple Sclerosis 
PRMS = Progressive Relapsing Multiple Sclerosis 
BBB = Blood Brain Barrier 
IFN = Interferon 
CSF = cerebrospinal fluid  
EAE = experimental autoimmune encephalomyelitis  
JCV = John Cunningham Virus 
DMF = Dimethyl-fumarate 
TMEV = Theiler’s murine encephalomyelitis virus  
MBP = myelin basic protein  
MOG = myelin oligodendrocytes glicoprotein  
PLP = proteolipidic protein 
MAG = myelin associated glicoprotein  
MHC-II = major histocompatibility complex class II 
DC = Dendritic cells 
APC = Antigen presenting cells 
NK = Natural Killer 
PML = progressive multifocal leukoencephalopathy 
GA = Glatiramer Acetate 
MRI = magnetic resonance imaging 
NT-3/4 = Neurotrophin 3/4 
SC = Spinal Cord 
MAPK = Mitogen-activated protein kinase 
PCD = Programmed cell death 
PARP = poly (ADP-ribose) polymerase 
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ERK = extracellular signal-regulated kinase 
PTX = Bordetella Pertussis Toxin  
PBS = Phosphate buffered saline 
CXCL =  chemokine (C-X-C motif) ligand 
CPM = counts per minute 
LFB = Luxol Fast Blue 
HE = Haematoxylin Eosin 
TEM = Transmission Electron Microscope 
HRP = horseradish peroxidase 
iNOS = inducible nitric oxide synthases 
mCC = medial corpus callosum 
IL = Interleukin 
TCL = T-cell line 
SEM = standard error of the mean 
SD = standard deviation
  
Introduction 
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Introduction 
 
Multiple Sclerosis 
 
Multiple Sclerosis (MS) is a chronic immune-mediated demyelinating and 
neurodegenerative disease of the central nervous system Noseworthy et al. 2000. 
This disease leads to a slower axonal conduction due to myelin damages and loss 
of neurons. First traces of MS description was between 1838 and 1842, when 
Jean Cruveilhier and Robert Carswell illustrated the lesions of MS almost 
simultaneously in the their respective atlas Compston 1988. In particular, 
Cruveilhier described symptoms like tiredness and paraplegia that histologically 
shown scars in spinal cord tissue.  Anyway, first full description was written by 
Jean Charcot in 1868 under the name “sclerose en plaques” by Jean Martin 
Charcot (Charcot, J. M., 1868): he was the first one to link disease symptoms 
and typical observed features, the sclerotic plaques. Furthermore, he carried on 
the histological work identifying, in the lesions, reactive gliosis, loss of myelin 
and phagocytes full of fatty acids, hypothesizing that was due to pathogens such 
as smallpox, typhoid and cholera infectionsi. 
 
 
Etiopathogenesis 
Onset of MS is therefore the results of interplay of many factors, like the genetic 
and environmental components. 
 
                                                          
i Raine C.D., McFarland H.F., Hohlfeld R., 2008. Multiple Sclerosis: a comprehensive text. 
Saunders Elsevier Editor 
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Epidemiology and environmental factors 
There are about 2.5-3 million people in the world with MS, 600.000 in Europe 
and about 114.000 in Italy. MS is usually diagnosed during early adulthood 
(although people can be diagnosed at any age) and that people are living with 
this progressive neurological disease for many decades.  
Due to its multifactorial nature, its distribution is not uniform: the disorder is 
more common in areas far from the temperate climate, particularly North 
Europe, the United States, New Zealand and South Australia. On the other hand, 
the prevalence of the disease seems to have a progressive reduction getting closer 
to equator.ii 
 
Furthermore, these geographic data could support the “hygiene hypothesis”, 
according to which subjects who are not exposed to infections at early age due 
to extreme cleaning conditions (as in developed countries), have aberrant 
responses to infections when affected by these infections during first adulthood. 
                                                          
ii https://www.aism.it/index.aspx?codpage=sclerosi_multipla, upd. June 2017 
Figure 1. Atlas of MS, 2013, Multiple Sclerosis International Federation (MSIF) 
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Examples of diseases which are likely to have a role in MS susceptibility if 
occurring later in life include poliomyelitis Nathanson and Miller 1978, 
infectious mononucleosis and measles. Infectious agents like Epstein-Barr virus 
(EBV), herpes simplex virus (HSV) and Chlamydia pneumonia (Cpn) are often 
suggested as etiologic factors in MS (Antony et al., 2004; Christensen, 2005; 
2010). Anti-EBV antibodies are high in MS patients and, after relapses, these 
patients often reactivate latent EBV infections. Wandinger et al. 2000. 
Sex is another factor in MS onset: this disease is twice more common among 
women than men, but this ratio is variable and local-depending: in fact, ratio of 
women:men with MS is considerably higher in some regions, such as East Asia 
where the female-to-male ratio is 3.0, and the Americas where it is 2.6. 
Nevertheless, usually men that develop MS that worsens more rapidly than 
women. 
 
Genetic factors 
 
Analogous to other autoimmune diseases, MS tend to cluster in families and 
several studies showed that monozygotic twins have an increased risk to develop 
MS in respect to unrelated population (Sadovnick 1993; Mumford et al. 1994). 
In part these studies were conducted in Finland and Denmark – two nations with 
an high incidence of MS cases - by Kuusisto and Hansen, respectively, on 
homozygous and heterozygous twins (Kuusisto et al. 2008 - Hansen et al. 2005). 
The overall trend is a higher concordance among monozygotic twins (25-30%%) 
than dizygotic twins (0-3%). In particular, Finnish researchers conducted a two-
time study, analyzing how incidence of MS was varied over the years, observing 
a higher concordance for dizygotic twins during last 20 years, increased up to 
15%. Also being siblings, but not twins, represents a risk factor: the risk in 
developing MS is greater for first degree relatives of patients affected by MS, 
with an incidence that can go from the 3% among brothers to 2% for parents and 
sons (Ahlgren et al. 2012 - Korn 2008 - Sadovnick 1993). Therefore, scientists 
support a complex combination of environmental and genetic factors responsible 
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of MS disease. Since the 1970s MS has been known to be associated with major 
histocompatibility complex class II (MHC) genes (Olerup and Hillert 1991). 
This gene is expressed by cells presenting the antigen and is important to induce 
a mediated CD4+ cell response. The gene encoding for this complex is, together 
with other genes involved in the functioning of the immune system, in a locus in 
position 6p21. It has been extensively studied with GWAS, observing that some 
HLA haplotypes may predispose to the disease. In the Caucasian population, the 
risk is attributed to the haplotype HLA-DR15: DRB1*15:01 (encoding HLA-
DR2b), DRB5*01:01 (expressing HLA-DR2a), DQA1*01:02, DQB2*06:02 
(encoding HLA-DQ6) (Ballerini et al. 2004 - Hoppenbrouwers and Hintzen 
2011). Homozygous DRB1*15:01 seems to be the phenotype correlated to the 
risk of MS onset, with the risk halved in DRB1*15:01/X heterozygous 
population. DRB1*15:01 has been also correlated with phenotypic markers of 
disease severity (Isobe et al. 2016). The first association studies showed that the 
idea of a polygenic model of MS heritability was the most appropriate and 
following this model research groups in Europe and USA started the assembling 
of large multicenter data sets in order to investigate by genome-wide association 
study (GWA study, or GWAS) the genetic correlation to MS occurrence 
(reviewed in Baranzini and Oksenberg 2017). GWAS studies allowed, for 
example, to confirm familiarity and to individuate associated genes (i.e. IL7R, 
CTLA4, and IL2RA between others) showing up to 200 autosomal associated 
susceptibility variants outside the MHC genes. Of note, there are some rare 
variants associated with the appearance of MS in certain populations, like in the 
Sardinian (Cocco et al. 2013 - Steri M et al. 2017). 
 
MS disease course 
 
As already mentioned, multifocal areas are the hallmark of this disease: this is 
the result of myelin loss within the central nervous system called plaques or 
lesions. Clinically, MS has manifestations that are dependent on nerve fibers 
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affected. The commonest manifestation is a visual disturbance, the optical 
neuritis, a set of symptoms as vision loss, painful eyes and blurred vision. Other 
typical manifestations are deficit or lacks in sensory, tremors, scanning speech 
and coordination defects and they can be attributed to an involvement of the 
cerebellum. (Stuke et al. 2009) Another disease feature is the manifestation of 
depression, that occurs with a prevalence range from 19 to 45%. (Skokou et al. 
2012) Besides these signs, inflammatory nature of disease is also reflected by 
CSF of patients, as higher concentration of total protein, mononuclear cell count 
and gammaglobulin (IgG) fraction (Compston 2006 – Popescu et al. 2013). 
There are usually schematically classified in four types of MS (Figure 2 - Kieseier 
and Hartung 2003): 
- Relapsing-Remitting MS (RRMS), that includes 90% of patients 
affected, secondary progressive MS (SPMS), and primary progressive 
MS (PPMS). (Manouchehrinia and Constantinescu 2012). Most MS 
patients (approximately 85%) initially present with this form of the 
disease, characterized by clearly defined disease relapses with full 
recovery or with sequelae and residual deficit upon recovery. RRMS is 
not classified as a progressive form of multiple sclerosis, but residual 
deficits can be established with each exacerbation.  
- Secondary progressive MS (SPMS). At least 50% of patients with RRMS 
will transition into this sub form, characterized by disease progression 
with or without occasional relapses, minor remissions, and plateaus.  
- Primary progressive MS (PPMS). Approximately 10% of the MS 
population presents a disease progression from the onset with occasional 
plateaus and temporary improvements.  
- Progressive-relapsing MS (PRMS). The least common form is a 
progressive disease from onset with acute relapses, with or without full 
recovery, with periods between relapses characterized by continuous 
progression.   
According to this subdivision, every type of disease is characterized by a specific 
clinical course: RRMS has well-known interspersed relapses during which there 
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is no disease progression followed by recovery of varying extent; conversely 
PPMS form has a progressive course of disease from the onset of illness. Last, 
SPMS starts as a RRMS showing a progressive pattern that may include relapses 
and remissions; it can occur after 5–25 years from disease onset, and the pattern 
often changes: the number of acute exacerbations is greatly reduced and replaced 
with a slow, steady increase in symptom severity. (Tremlett et al. 2009).  
Furthermore, Fred Lublin (Lublin 2014) overhauled and redefined the RR and 
Progressive Disease, taking in consideration either clinical signs and images 
(MRI). His intentions were to make it easier to characterize the state of the 
disease, considering the clinic and the instrumental images. Defining the active 
or inactive state of the disease, especially for the progressive phase, this new 
subdivision would have helped to track the right disease phase. 
He considers the Clinically Isolated Syndrome (CIS) as part of RR disease 
spectrum, and subdivided CIS and RR in active or not active (fig. 2). Moreover, 
PPMS and SPMS were collected in a generic Progressive Disease voice, 
subdividing it in (fig. 2): 
• Active and with progression: individual has had an attack and is also gradually 
worsening) 
• Active but without progression: e.g. individual has had an attack within a 
previous specified timeframe, i.e. 1 year, 2 years 
• Not active but with progression: e.g. walking speed has decreased) 
• Not active and without progression: stable disease. 
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Figure 2. Illustration of different clinical courses of multiple sclerosis reviewed by Fred Lublin 
in 2013. Lublin 2014 
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MS therapies 
Final goal of MS treatment is treating, avoiding and diminishing relapses, then 
slowing progression of disability. Basically, there are two different strategies: a 
short-term one to reduce damage effects after an acute relapse, and a long-term 
one, that aims at stabilizing disease processes. (Spain et al. 2009) 
Thanks to their potent immunosuppressive and anti-inflammatory potential 
through induction of T-cell apoptosis, glucocorticosteroids have represented the 
first lines of treatment since 1960s. Adrenocorticotropic hormone (ACTH) is a 
melanocortin peptide that was approved by the FDA for use in humans in 1952, 
only three years after it was first tested in rheumatoid arthritis (RA) (Henche PS 
et al., 1949), but it caused unselected release of steroids from adrenal glands. 
Later, methylprednisolone and prednisolone have been the MS therapies were 
mostly based on their assumption. 
Nowadays, these corticosteroids are still used during acute relapses because their 
anti-inflammatory properties make them perfect to slower disease progression 
and relapse duration through T-cell lymphocytes apoptosis (Gold et al. 2001) and 
accelerates reconstitution of blood brain barrier (BBB). For relapsing treatment, 
a high dosage steroid-based therapy (500-1000 mg/die) is recommended. 
Intravenous methylprednisolone is usually administered for 3-7 days and is 
followed by prednisolone (60-80 mg/die) if symptoms are particularly severe.  
So far, from 1993 when IFN-β1a has been approved by FDA as drug for 
Relapsing-remitting multiple sclerosis (RRMS) treatment, a lot of therapies and 
drugs has been developed and approved. During these years, drugs helped the 
MS understanding, leading to new discoveries and, conseguently, categorisation 
of MS in relapsing and progressive course (Comi et al. 2017).  
Ransohoff et al. in 2015 outlined history of disease-modifying drug for MS in 
three distinguished temporal eras: 
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Figure 3. Schematic timeline for the development of disease-modifying drugs for MS. 
Abbreviations: CSF, cerebrospinal fluid; EAE, experimental autoimmune encephalomyelitis; 
JCV, polyomavirus JC; MS, multiple sclerosis; PML, progressive multifocal 
leukoencephalopathy; RRMS, relapsing–remitting. (Ransohoff et al. 2015) 
The representative drugs of the first era were IFN-β1 and glatiramer acetate, two 
immunomodulator drugs. The approval of IFN as drug for RRMS treatment by 
FDA in 1993 opened the first era (Hauser et al. 1983). Until then, strategies were 
intravenous methyl-prednisolone-based.iii IFN-β1 was demonstrated to have a 
positive effect in reducing inflammatory cells migration in CNS, in inhibiting T 
lymphocytes proliferation, proinflammatory cytokines production and in 
stimulating the production of anti-inflammatory ones (Yong et al. 1998). 
IFN-β is marketed in three different formulations: Avonex (IFN-β-1a; 30 mg 
I.M. 1/wk), Rebif (IFN-β-1a; 22 or 44 MG S.C. 3/wk) and Betaferon (IFN-β-1b; 
250 mg S.C. every other day). Developed for RR-MS form patients, IFN-β-1b 
showed to be effective also in the SP-MS forms (SPECTRIMS Study Group, 
2001). Randomized and controlled double-blind multicenter clinical trials versus 
placebo, such as prisms-4 and OWIMS, demonstrate that the use of IFN-β 
reduced the risk of relapsing of about 30% and it reduced the emergence of new 
MRI lesions of about 70% (prisms Study Group, 2001; OWIMS Study Group, 
1999).   
                                                          
iii Interferon β-1b is effective in relapsing-remitting multiple sclerosis. Part I and II. Clinical 
results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple 
Sclerosis Study Group. Neurology 43, 655-661 and 662–667 (1993)).  
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Glatiramer acetate (GA) is a random polypeptide made up of four amino acids 
(L-glutamic acid, L-lysine, L-alanine, and L-tyrosine) in a specific molar ratio. 
GA causes an immune deviation from a Th1 to a Th2 phenotype, induces 
antigen-specific T-suppressor cells that cross-react with putative autoantigens in 
the CNS, and inhibits antigen presentation. (Yong et al. 1998 – Neuhaus et al. 
2001). It also represents the best safety profile for pregnant women with not very 
severe disease.  
The second era is marked by the introduction of monoclonal antibodies and small 
molecules in therapies: MS therapeutic development further evolved, and  it is 
characterized by approvals of natalizumab (monoclonal antibody, 2003) and 
fingolimod (a sphingosine-1-phosphate receptor modulator, 2009). 
Natalizumab is a monoclonal antibody to integrin-alfa4-beta1 in leukocytes that 
showed its efficacy in disease suppression in the rodent model of MS, EAE. 
(Yednock et al. 1992) Natalizumab can be used as monotherapy in RRMS cases, 
it demonstrated its efficacy in reducing clinical relapses, disability progression, 
and magnetic resonance imaging (MRI) disease activity measures. (Polman et 
al. 2006). It interferes with T cells entrance in the brain and avoiding 
inflammation and reducing and retarding relapses. (Barten et al. 2010). Despite 
the good clinical results, this therapy has  been linked with a progressive 
multifocal leukoencephalopathy (PML), a rare, demyelinating opportunistic 
infection of the CNS caused by the John Cunningham virus (JCV) (Langer-
Gould  et al. 2005 - Buck and Hemmer 2011 – Clifford et al. 2010).  
Fingolimod (FTY720) is a pro-drug derived from Isaria Sinclairii and that is 
converted in vivo to sphingosine S1P analog, becoming a S1P receptor 
modulator. The latter is downregulated on leukocytes and the endothelium, 
trapping naïve and central memory T lymphocytes in lymph nodes (Brinkmann 
2009). Although it has a high therapeutic index with a 55-60% lower relapse 
rates and MRI-activity reduction, this medication has a potential safety problem 
due to its low target specificity. Indeed, fingolimod is able to bind four of the five 
known S1P receptor and it can affect other cells then lymph-node, as vascular 
endothelium, arterial smooth muscle cells, atrial myocytes, bronchial smooth 
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muscle, and CNS astrocytes and oligodendrocytes (Pelletier and Hafler 2012). 
For this reason, this therapy requires a very strict safety-monitoring protocol. 
The third era (2009 to present) includes small molecules, antibodies and 
biologics drugs. Examples are teriflunomide, dimethyl-fumarate and 
Alemtuzumab. The first one is a pyrimidine synthesis inhibitor, exploiting its 
function with inhibition of the mitochondrial enzyme dihydro-orotate 
dehydrogenase (DHODH), an enzyme expressed at high levels in proliferating 
lymphocytes (Ruckemann et al. 1998). 
Dimethyl-fumarate (DMF) is an immunomodulator drug that seems to have the 
activation of the transcription factor nuclear (erythroid-derived 2) related factor 
(Nrf2) as mechanism of action. (Linker and Gold 2013) By activating this 
transcription factor, DMF enhanced neuronal survival and protected glial cells 
against oxidative stress. (van Horssen et al. 2010)  
Alemtuzumab is a monoclonal antibody that has as target CD52, a highly 
expressed protein on monocytes, CD4+ and CD8+ T cells. It promotes 
complement and cell-mediated lyses of targets. Patients who use it show 
reduction of inflammatory activity and decreased CNS lesions due to some 
immune cell subsets reduction, shifting the lymphocyte profile. (Compston 
Compston 2006).  
Present days link to a more rational approach, based on effectiveness versus 
safety and tolerability. (Ransohoff et al. 2015) 
 
Use of animal models for MS research 
As said, MS is a very complex disease that involves several genetic and 
environmental risk factors and, based on this, some therapies have been 
developed to modify disease course. Animal models surely played and will play 
an important role to improve therapies for MS. Taken the complexity of this 
disease and its unknown etiology, a single animal model can’t cover the entire 
spectra of all aspects of pathology and clinical feature of human MS.  
Three are the main commonly studied animal models for MS (Denic et al. 2011): 
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- purely Experimental Autoimmune/Allergic Encephalomyelitis (EAE) 
- toxin-induced models of demyelination, including the cuprizone model. 
 
Experimental Autoimmune Encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is, in general, a good model 
to study the inflammation in the brain (Baxter 2007) and one of the most used 
animal model for MS, with over 6000 publications listed on PubMed. It can be 
induced by active or passive immunization of different animal species such as 
mice, rats and monkeys (marmoset) or genetically modified animal models such 
as the mouse strain C57BL/6 mice, that express 1-9 peptide-T cell receptors 
specific for myelin basic protein (MBP) (Zujovic et al. 2012). As said, in general 
there’s no model which reproduces all aspects of MS and, in particular, there’s 
no a unique EAE model that allows to emulate one or more characteristics of the 
disease (Schmidt 1999 - Van Epps 2005 - Hafler et al. 2005). 
 
Historical notes  
The birth of EAE model dates to 1925, when Koritschoner and colleagues found 
that rabbits immunized with homogenate of human spinal cord developed 
paralysis (active induction) (Koritschoner, R. 1925). In 1933 Rivers and 
colleagues (Rivers et al. 1933) explained that the paralysis, that arose in monkeys 
immunized with brain tissue homogenate, was associated with perivascular 
infiltrates and tracked to demyelination in central nervous system (CNS) (brain 
and spinal cord). Freund's adjuvant introduction in 1942 (Freund Freund et al. 
1947) boosted immune response improving and facilitating the immunization. 
The first passive induction of EAE has been proposed by Paterson in 1960 
(Paterson 1960), when he demonstrated that EAE could be induced transferring 
lymph node cells isolated from rats immunized with spinal cord homogenate, to 
naive animals. The addition of pertussis toxin in 1973 improved efficiency in the 
induction of disease. Nowadays, it has become clear that the clinical outcome of 
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immunization depends on genetic background of animals studied, the type of 
antigen and following immunization protocol (Hartung et al. 2005 - Olsson et al. 
2000; Wekerle et al. 1994) 
 
EAE models 
Over the years, the material used for the immunization protocol changed (passing 
through the homogenate of CNS towards the immunodominant myelin proteins 
and peptides) allowed to increase the reproducibility of EAE models, more 
faithful to the different aspects of MS (Wekerle et al. 1994). Among myelin 
proteins, MBP is the most used (Martenson et al. 1969): 
- MOG, myelin oligodendrocytes glicoprotein (Lebar and Vincent 1981) 
- PLP, proteolipidic protein  
- MAG, myelin associated glicoprotein (Poduslo 1983) 
and among encephalitogenic small peptides usually this is the list of the most 
used (Eylar et al. 1970):  
- MBP1-37 
- MBP1-11  
- MBP1-9 
- MBP83-99  
- MOG35-55  
- PLP139-151. 
 
Each mouse strain is susceptible for specific antigen protein or only for certain 
synthetic peptides. The combination mouse strain/antigen determines the type of 
illness, EAE, which will be received. For example, immunizing mice of 
C57BL/6 strain with syngeneic MOG35-55, Freunds’ complete adjuvant (CFA) 
and pertussis toxin (PTX), it will be obtained an EAE presenting an acute phase 
followed by a brief remission until the onset of a chronic form characterized of, 
especially in the spinal cord, demyelination and axonal loss with macrophage 
and CD4+ T-lymphocytic infiltrates.  
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Main MS animal models are resumed in  
Table 1. 
 
 
Table 1. Classical models of di EAE. Abbreviations: DA, Dark agouti; EAE: Experimental 
Autoimmune Encephalomyelitis; MBP: Myelin Basic Protein; MOG: Myelin Oligodendrocyte 
Glycoprotein; PLP, Proteolipid protein. (Adapted from Batoulis et al. 2011 ); MP4: a chimeric 
recombinant fusion protein of myelin-basic and proteolipid protein. 
     
Choice of EAE model 
The variability of EAE models is due to species susceptibility and strain 
immunized with different myelin antigens. The combination strain-antigen and 
choice immunization protocol are important for the success of immunization and 
for the development of a specific EAE form (Steinman 1997). Each animal 
species and each strain of each species has a different genetic background that 
gives it a different susceptibility to antigens (Luckey et al. 2011). In the Decade 
1960-70 it was discovered that the MHC genes were essential for all immune 
responses to protein antigens. Baruj Benacerraf, Hugh McDevitt and other 
researchers found that strains of rats or mice differed in their ability to produce 
antibodies against simple synthetic polypeptides and responsiveness was 
DISEASE COURSE ANIMAL STRAIN ANTIGEN 
RELAPSING-REMITTING Mouse SJL/J PLP: 139-151 
RELAPSING-REMITTING Mouse C57BL/6 Low dose MOG35-55 
RELAPSING-REMITTING Rat DA MOG1-125 
CHRONIC Mouse C57BL/6 MOG35-55 
CHRONIC Mouse C57BL/6 PLP178-191 
CHRONIC Mouse C57BL/6 MP4 
CHRONIC Rat Lewis N1 MOG 
MONOPHASIC Mouse B10.PL MBP 
MONOPHASIC Mouse PL/J MBP 
MONOPHASIC Rat Lewis MBP 
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inherited as a Mendelian dominant character. Genetic predisposition is 
particularly important for the possible development of the disease. The 
combination strain/peptide has a great relevance for the assignation of the type 
of inflammatory infiltrate in the CNS (Berger et al. 1997; Kuerten et al. 2010). 
Myelin antigens generate inflammatory infiltrates of several different cellular 
subtypes in CNS, allowing to evaluate in distinct patterns the high variability of 
lymphocytic infiltrates in MS. For example, the EAE model, induced with 
MOG35-55 peptide in C57BL/6, especially studies Th1 and Th17 lymphocytic 
infiltrates and generates a chronic course. Lymphocytic response-antigen-
specific causes lesions in CNS and a wide variety of clinical signs and different 
types of EAE: acute (for example in Lewis rat), chronic (C57BL/6 or mice 
Biozzi ABH) or relapsing-remitting MS (SJL mice). 
The choice of a EAE model depends on disease aspects of interest.  
 
EAE pathogenesis 
Naїve T cells present in animal blood can be potentially autoreactive: once 
escaped the immune tolerance, these cells could be specific to myelin proteins. 
This mechanism is exploited with animal immunization strategy: it usually 
provides the use of a myelin-associated antigen and an adjuvant, and leads to an 
autoimmune disease arising from a breakdown of immune tolerance in T cells 
specific for myelin antigens (Seamons et al. 2003). The presentation of the 
antigen to T-cells by antigen presenting cells (APCs), such as dendritic cells 
(DC). Once activated, T lymphocytes reach CNS, via bloodstream, penetrating 
the blood brain barrier (BBB - Wekerle et al. 1994): immunization compromises 
BBB integrity encouraging lymphocytes, DC and activated macrophages to 
migrate toward the CSF. T-cells specific to myelin antigens are reactivated in 
CNS by infiltrated and residents DCs and consequently they produce 
proinflammatory cytokines that activate infiltrated macrophages, astrocytes and 
microglia. The release of proinflammatory cytokines (IFN-γ, TNF-α, IL-17, 
TGF-β, NO, IL-6) causes oligodendrocyte loss inducing demyelination and 
axonal injury (Figure 4). Immune-mediated tissue damage or hypersensitivity 
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can be mediated by auto-specific IgG antibodies. Pathology results from 
activation of complement and antibody-dependent cellular cytotoxicity (ADCC), 
mediated by inflammatory effector leukocytes that include macrophages, natural 
killer cells and granulocytes. Antibodies and complement have been associated 
to demyelinating pathology in MS lesions, whereas macrophages predominate 
among infiltrating myeloid cells (Khorooshi et al. 2015). The presence of anti-
aquaporin 4 (AQP4) antibodies is another important immunological feature 
implicated in demyelination. AQP4-IgG can cause ADCC when effector cells 
are present and complement-dependent cytotoxicity (CDC) when complement is 
present (Saadoun et al. 2010). Although researchers believed for many years that 
Th1 lymphocytes were responsible of the disease, more recent studies have 
highlighted the role of another lymphocyte subpopulation: Th17. The 
differentiation of T helper cells into Th1 required cytokines such as IL-12 and 
INF-γ, that induces the expression of specific transcription factors as T-bet. 
Differentiation in Th-17, instead, is induced by IL-6, IL-23 and TGF-β cytokines 
that induce the expression of RORC transcription factor. Th1 and Th17 
populations can have a phenotypic plasticity that converts Th1 in Th17 and vice 
versa. Such plasticity comes from rapids epigenetic modifications that silence T-
bet or RORC gene depending on the received stimulus. EAE development is an 
alteration of balance between inflammatory responses mediated by Th1 and Th17 
and function of regulatory T cells that promote tolerance to self. Initially, in 
EAE, regulatory role was  attributed to T CD8+ effector cells (Koh et al. 1992) 
and later also to natural Killer cells (Zhang et al. 1997). More recent works 
recognized the regulatory role to T cells expressing CD4+CD25+ and Foxp3 
transcription factor. Disease progression takes place by a process known as '' 
epitope spreading '': within a few weeks of onset of EAE, begins a tissue damage 
that results in the release of new epitopes, which are processed and presented by 
APC found in the CNS, which express high levels of MHC II and costimulatory 
molecules. Then activation of brain tissue induces activation of autoreactive T 
cells which recognize myelin proteins other than antigen that initially triggered 
the disease. Clinical significance of this phenomenon is the fact that, at a time 
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when the disease is advanced, it is likely that multiple antigens are involved in 
disease progression. Another cell population involved in MS and EAE 
immunopathogenesis is represented by B lymphocytes. These cells play a dual 
role, i.e. they act both as antigen-presenting cells that as autoantibody producing 
cells (Franciotta et al. 2008). The antibody production against MOG is crucial 
because this phenomenon increases disease severity causing extensive 
demyelination. The sequence of events that lead to EAE pathogenesis is the same 
in both active and passive induction (Goverman et al. 1993). However, inducing 
passive autoreactive T cells are isolated from lymphoid tissue of an animal 
previously immunized with myelin antigen, stimulated in vitro and transferred 
to a naïve receiver.  
 
 
Figure 4. Pathogenic cascade in the periphery and central nervous system (CNS) during 
experimental autoimmune encephalomyelitis (EAE). From Dendrou et al. 2015. 
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EAE pathogenesis induced with MOG35-55 peptide. After immunization with 
MOG35-55 peptide, peripheral lymph nodes, dendritic cells (DC) and naїve T cells 
are activated aganst the antigen. Activated T-cells (Th1 and Th17) enter into 
bloodstream and reach central nervous system (CNS) crossing the blood-brain 
barrier (BBB). T-cells in CNS are recruited by periphery inflammatory 
molecules that activate microglia and APCs (antigen presenting cells). T-cells 
expand and continue to produce inflammatory molecules that destroy myelin 
resulting in axonal damage. (Fletcher et al. 2010)  
 
EAE, limits and application 
EAE mouse models can be used in order to associate clinical manifestations with 
data derived by histopathology and inflammatory mechanisms, that are involved 
in MS. The model is one of the most studied for new MS therapeutic approaches 
but with obvious limitations. The first limitation is that to date the model is not 
a spontaneous model of disease, it is always necessary an induction of disease by 
immunization, although there are some models of transgenic mice that express 
T cell receptors specific to myelin, which partly reproduce a spontaneous onset 
of illness (Goverman et al. 1993). The second limitation of EAE is that myelin 
synthetic peptides don’t undergo post-translational modification (PTM) along 
the production pathway as with in vivo endogenous myelin proteins (Zhou et al. 
1995). Schematically, the ribosome translates a mRNA sequence into a protein 
and releases it through the endoplasmic reticulum; here, the protein is cut, folded 
and held in shape by disulfide (-S-S-) bonds. Consequently, the protein passes 
through the Golgi apparatus, where it is packaged into a vesicle. Here the protein 
is subjected to last proteolysis modifications and it turns into mature protein 
(Potelle et al. 2015). So, it is possible that lymphocyte populations activated by 
synthetic peptides could be different from those triggered by processed peptides. 
The third limitation is in the exclusive role of CD4+ T in mediating EAE, where 
human disease sees an important role of CD8+ T lymphocytes (Lassmann and 
Ransohoff 2004). Finally, we must always remember the phylogenetic distance 
that exists between man and mouse.  
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For all these considerations, while recognizing the value of this model, it is still 
difficult to exploit the results obtained in EAE in order to predict the efficacy of 
treatments in human disease and over time there have been both important 
successes that serious failures (Sriram and Steiner 2005). 
 
Toxic model of demyelination: Cuprizone 
Cuprizone [bis–cyclohexanone-oxaldihydrazone] is a copper chelating reagent, 
which supplemented to normal rodent chow, directly or indirectly causes 
oligodendroglial cell death with subsequent demyelination. Once demyelination 
is complete new oligodendrocytes, generated from the pool of oligodendrocyte 
progenitors (OPC), begin to form new myelin sheaths (Gudi et al. 2014). Toxins, 
such as cuprizone, provokes demyelination in the absence of inflammatory 
infiltrates. Lacking lymphocytic inflammatory component this model is adopted 
mainly to evaluate the demyelination and re-myelination. Instead, intracerebral 
inoculation of murine encephalomyelitis virus is used to study possible 
mechanism involved in autoimmune reactions triggered by viral infection, as it 
is thought to occur as a result of EBV infection (Abbas et al. 2007). The 
mechanism by which the virus acts has not yet been clarified: for example, it can 
be hypothesized that active viral infects resident APC, leading to an increase of 
costimulatory molecules expression, such as to break tolerance and encouraging 
autoimmune diseases reactions to self-antigens; or there could be a phenomenon 
of molecular mimicry, so through mechanisms of cross reactivity-specific T cells 
recognize myelin self-antigens, viral antigens. From an epidemiological point of 
view viral infections have been associated with a clinical exacerbation of the 
disease, so it seems unlikely that these factors are the etiologic factors of 
demyelination. 
 
Neurotrophins and NGF 
Neurotrophins are a class of cytokines able to rule development, growth and 
survival of a large number of cells, not exclusively from nervous system 
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(Reichardt 2006 – Caporali and Emanueli 2009). In CNS these molecules are 
necessary for the development and maintenance of the vertebrate nervous 
system, neural regeneration and remyelination (Kerschensteiner et al. 2003).  
Nerve Growth Factor (NGF) was the first and best characterized member, 
discovered by Rita Levi Montalcini and Cohen in 1956 during the study of chick 
embryonal development. Levi-Montalcini clearly demonstrated that in chick 
embryos the production of this diffusible factor in the target organ was 
responsible for the survival of peripheral neurons during development (Levi-
Montalcini and Hamburger 1951). The activity of NGF is not restricted to 
embryonal life: during adulthood there is a basal production of NGF in the 
innervation field that is essential in regulating neuronal plasticity: experiment 
based on antibodies that neutralized the growth factor caused a selective 
depletion in sympathetic chains, leading to hypothesize the central model of 
neurotrophic factor action.  (Cohen 1960 - Levi-Montalcini and Booker 1960). 
Later, other members of neurotrophic factors and member of NGF family of 
growth factor was discovered in mammals: Brain Derived Neurotrophic Factor 
(BDNF, Barde et al. 1982), Neurotrophin 3 (NT-3, Hohn et al. 1990) and 
Neurotrophin 4/5 (NT-4/5, Berkemeier et al. 1991) and 6 (NT-6, Gotz et al. 
1994). A schematic potential activity of neurotrophins with their receptor is 
reported in Figure 5: mature neurotrophic factors binds their high affinity 
receptors (NGF-TrkA, BDNF and NT-4-TrkB and NT-3-TrkC) and induce an 
heterodimerization with p75NTR receptor. 
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NGF, a cross-talk molecule between neuronal and immune cells 
 
The Nerve Growth Factor has a structure that is composed by three subunits, 
named α, β and gamma: their interaction leads to constitute an high molecular 
weight 7S complex, with a final weight of 130-140 kDa. (Vega et al. 2003). NGF 
interacts with two distinct receptor chains, a high-affinity receptor belonging to 
the Tropomyosin receptor kinase A (TrkA, 140 kDa) and a low affinity one, 
p75NTR (NTR stands for Neurotrophin Receptor) that binds all neurotrophins 
(Villoslada and Genain 2004). 
These receptors are transmembrane proteins that are made up of three parts, that 
comprises transmembrane, extracellular and intracellular domains. Once bound 
with these membrane receptors through their extracellular domains, NGF 
induces the dimerization, exerting trophic and differentiation functions. Trophic 
Figure 5. Schematic representation of the effect of interaction of neurotrophins with their 
receptor. Adapted from Meeker and Williams 2015. 
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function involves the apoptotic events inhibitions, while the latter one triggers 
growth and modeling of axons and dendrites. 
High-affinity receptors are not exclusively expressed on nerve cells: they’re also 
present on deep-tissue and lymphoid and epithelial cells. As matter of the fact, 
one of the most increasing evidences is that NGF can also exert specific effects 
on immune functions. For example, treatment of young rats with NGF before 
and after immunization with sheep erythrocytes results in an enhancement of T 
lymphocyte-dependent Ab synthesis (Manning et al. 1985); NGF can also induce 
shape changes in platelets as demonstrated in rabbit model (Gudat et al. 1981); 
growth factor is able to enhance vascular permeability in the rat skin (Otten et 
al. 1984), and causes degranulation of rat peritoneal mast cells, suggesting that 
NGF is involved in acute inflammatory responses (Bruni et al. 1982). 
Furthermore, NGF promotes colony growth and differentiation of myeloid 
progenitor cells (Matsuda et al. 1988) and induces lymphocyte proliferation of 
both B and T cell populations (Thorpe and Perez-Polo 1987). Functional NGF 
receptors have also been demonstrated on human B lymphocytes (Brodie and 
Gelfand 1992) implying that NGF may act as a B cell growth factor.  
In summary, NGF can induce proliferation and differentiation of B cells into Ig-
secreting cells and the presence of functional NGF receptors on human blood 
monocytes (Kimata et al. 1991 - Ehrhard et al. 1993) suggests that NGF, in 
addition to its neurotrophic functions, can act as an immunomodulator, mediating 
the cross-talk between nervous and immune systems. 
 
NGF pre-clinical studies 
The biological effects of NGF are primarily mediated via its high affinity 
receptor-TrkA. In 2003 B. Oderfeld-Nowak and colleagues (Oderfeld-Nowak et 
al. 2003) examined the effect of EAE on the expression of TrkA in neuronal and 
non-neuronal cells of spinal cord (SC) of Lewis rat during the acute (14 days 
postimmunization, dpi) and chronic (12 months postimmunization, mpi) phases 
of disease. Under EAE conditions, they noticed an upregulation of TrkA on 
astroglia associated with an immunoreactivity; moreover, the researchers 
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verified their hypothesis according to which in the acute phase of disease there 
was an up-regulation of this receptor in the population of oligodendroglia in the 
white matter. On the contrary, TrkA was not seen in the chronic phase of the 
disease. These results suggested that both neuronal and glial TrkA expression 
changes depend on inflammation, indicating that during the acute phase of EAE 
the glial cells become more receptive for NGF, marking glia cells as an important 
target for pharmacological manipulation, particularly for exogenously 
administered NGF. 
 
NGF clinical studies 
Studies on inflammatory and autoimmune diseases showed an abnormal 
activation of immune cells and an increased production of cytokines and revealed 
a localized increase in NGF levels at the sites of inflammation. Enhanced NGF 
levels were initially found in the CSF of MS patients, and it was shown that an 
increase in NGF closely follows the course of the disease (Bracci-Laudiero, L. 
et al.; 1992). The list of inflammatory diseases characterized by an enhanced 
production of NGF in the inflamed tissues or in the blood is fairly long and 
includes diseases with different pathogenic mechanisms (Bonini et al. 1996; 
Stanzel et al. 2008). Inflammatory cytokines can induce the synthesis of NGF in 
neuronal and glial cells, as well as in epithelial, endothelial, connective and 
muscle cells (Figure 6) (von Boyen et al. 2006) and there are also other 
molecules that can up-regulate the basal production of NGF in tissue as 
prostaglandin (Bullo et al. 2005) and histamine (Lipnik-Stangelj and Carman-
Krzan 2004). 
Recently, NGF was associated to autoimmune disease and inflammation: 
Prencipe et collegues (Prencipe et al. 2014), demonstrated that NGF 
downregulates inflammatory response in human monocytes via TrkA pathway, 
interfering with the response of TLR-activated monocytes and inducing the 
downregulation of pro-inflammatory cytokines. 
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BDNF 
The brain‑derived neurotrophic factor (BDNF) is a 27‑kDa basic protein and is 
one of the most potent factors that support neuronal survival, regulating 
neurotransmitter release and dendritic growth (Kerschensteiner et al. 1999) 
binding TrkB and p75NTR receptors.  
This NGF family member is mainly produced by immune cells, neurons and 
activated astrocytes present in inflamed areas of neurodegenerative disease 
(Stadelmann et al. 2002); it has also been found in thymus and spleen. 
Furthermore, in vitro studies show that T and B cells and monocytes expressed 
BDNF in neurodegenerative lesions. 
Several studies highlighted the BDNF ability in preventing neuronal 
degeneration and inducing oligodendrocyte proliferation and myelination in 
some forms of neuronal injury (McTigue et al. 1998), making of this 
neurotrophic factor a possible therapeutic target. 
Figure 6. Direct and indirect effects of NGF on inflammatory responses. At the site of inflammation, 
inflammatory cytokines induce (blue arrows) the production of NGF in different cell types, such as muscle cells, 
epithelial cells, fibroblasts, adipocytes, neurons, glia, and immune cells. The enhanced local production of NGF 
influences nerve fiber distribution and neuronal activity, inducing the synthesis and release of neuropeptides and 
neurotransmitters that have immunomodulatory effects. NGF receptors are also expressed on the membrane of 
immune cells and NGF can directly modulate the activity and functions of immune cells (Minnone et al. 2017). 
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NGF and its role as anti-apoptotic agent 
NGF is a potent pro-survival factor 
The interaction of NGF with TrkA activates molecular circuits mediated mainly 
by PI3K-Akt and MAP kinases that block both the intrinsic and apoptotic 
pathways (Ichim et al. 2012), thus maintaining cell survival under various stress 
conditions. It has been described that NGF is able to deactivate p38 MAPK and 
JNK, two enzymes involved in the induction of the apoptotic process (Weston 
and Davis 2007) in nerve cells undergoing metabolic stress. In memory B cells, 
neurotrophin acts as an autocrine survival factor contributing to maintaining the 
structural and functional integrity of Bcl-2 protein. This function is exerted 
through the continuous inactivation of p38 MAPK, an enzyme able to 
phosphorylate Bcl-2 and induce functional deficiency (cytochrome c release and 
caspase activation) [Torcia et al. 2001]. 
Here we particularly describe, in detail, molecular mechanism of apoptosis that 
are inhibited by NGF-TrkA triggered pathway. The schematic representation of 
apoptosis pathway in presence or not of NGF are schematically resumed in 
figure below. 
 
Schematic representation of the pathway triggered by the presence of NGF: binding its High-
affinity receptor and p75NTR, it induces their heterodimerization and triggering a kinase cascade 
that culminates with the suppression of apoptosis. 
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Molecular mechanism of apoptosis 
Cell death is a process that can be triggered by many stimuli. The main 
mechanisms of cell death are necrosis and apoptosis (Krysko et al. 
2008). Necrosis is a pathological process, unleashed in response to an acute 
injury such as hypoxia, hypothermia, radiation, viral infections, immune 
response, chemicals and drugs (Israels and Israels 1999). These events lead to a 
loss of integrity of the membranes of organelles including nucleus, resulting in 
the release of their contents (ATP, protease and lysozymes), up to the failure of 
the whole cell and DNA degradation in non-specific ways. This phenomenon, 
which the cell undergoes passively, triggers an inflammatory response with 
release of pro-inflammatory cells including macrophages. 
In contrast, apoptosis is a term that can be used to describe the programmed cell 
death (Programmed Cell Death; PCD), a cellular mechanism genetically 
controlled and highly conserved during evolution (Metzstein et al. 
1998). Described in all multicellular eukaryotes (Ellis et al. 1996), apoptosis is a 
physiological event that occurs during the early stages of development and plays 
a key role in morphogenesis (Jezek and Kozina 2009), in sexual differentiation 
and epigenetic processes of auto immune and nervous system organization. 
Furthermore, balancing the relationship life/death of damaged cells allows tissue 
homeostasis in adults (Orrenius et al. 2003). Therefore, apoptosis is a finely 
regulated process, in which the cell is actively involved with many 
morphologically and biochemically well-defined events. Cellular changes begin 
with a cell rounding, which entails the loss of contact with surrounding cells and 
the disappearance of their membrane structures like microvilli and specific 
regions of contact with other cells. At the same time, the loss of water and ions 
reduces cell volume resulting in cytoplasmic condensation (Kerr 2002). At 
nuclear level some events happen: the loss of the nucleolus and the chromatin 
condensation in dense and circumscribed clusters which accumulate on the 
nuclear membrane (pyknotic core).  
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Subsequently, the nuclear matrix is solubilized, leading to the DNA exposure to 
the enzymatic attack by nucleases, which result in breakage of the nucleic acid 
in high molecular weight fragments. At the end of chromatin condensation, the 
nucleus looks destroyed in fragments that contain even cellular organelles 
(mitochondria and endoplasmic reticulum portions), surrounded by the nuclear 
membrane or casted in protuberances, which are formed at the surface of the cell 
(blebs). The plasma membrane that surrounds these protuberances welds, giving 
rise to "apoptotic bodies", quickly absorbed and digested by macrophages 
(Krysko et al. 2008).  
Two have been identified: the extrinsic apoptotic pathways, receptor-mediated 
(Ashkenazi and Dixit 1998), and the intrinsic pathway, also known as 
mitochondrial pathway (Green and Reed 1998). Although these two pathways 
are distinct, are not clearly separated from each other. 
A key phenomenon of cell apoptotic cell death is an exclusive class of proteases 
known as caspases aspartate-specific. Between these 3 classes have been 
identified, 2 of which play important roles in apoptosis: one can distinguish the 
initiators caspases (Caspase-2, -8, -9 and -10) and performers caspases (Caspase-
3, -6 and -7); the third group is the inflammatory caspases (Caspase-1, -4, -5, -
11 and -12). The caspase activation is a process that provides for the activation 
of Caspase initiators through auto-cleveage and, the proteolytic cleavage of 
Caspase performers by these enzymes. Once activated, caspases performers 
induce the activation of other substrates such as cytokeratins and poly (ADP-
ribose) polymerase (PARP). The intrinsic and extrinsic activation pathway of 
apoptosis intersect at a common point represented by the activation of effector 
caspases -3, -6 and -7. 
The exposure of the death domain (DD) molecular adapter (FADD, Fas-
Associated protein with Death Domain; TRADD, TNFR Associated protein 
with Death Domain) is the main event of extrinsic pathway. DD domains 
exposure occurs upon activation of its membrane receptors as FAS, TNFR. The 
exposure of those domains DD induces the procaspase-8 and -10 
recruitments. From the assembly of these proteins come out a complex 
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called Death-Inducing Signaling Complex (DISC) in which the molecules of 
proenzyme can activate itself, thanks to partial coupling and intrinsic protease 
activity (Boatright and Salvesen 2003). The initiators caspase activates the 
effector ones, that affect specific substrates as cytokeratins, cytoskeletal proteins, 
PARP and nuclear protein NuMA, responsible for the biochemical and 
morphological changes observed in apoptotic cells (Elmore 2007). 
The intrinsic pathway of apoptosis is mainly triggered by events that affect 
mitochondrial membranes homeostasis. Bcl-2 family proteins plays a key role in 
maintaining proper mitochondrial membrane permeability. In the family of Bcl-
2 in fact recognize both anti-apoptotic proteins such as Bcl-2, Bcl-xL, Bcl-1 and 
Bcl-w, both pro-apoptotic proteins like Bax, Bad, Bid or Bim (Elmore 2007; 
Cory and Adams 2002). The Bcl-2 family is controlled by p53 in turn involved 
in inhibiting neoplastic transformation. The first consequence of the intrinsic 
pathway of apoptosis activation is the increased permeability of mitochondria 
through mitochondria permeability transition pore (MPTP), induced by inner 
mitochondrial membrane changes and, consequently, the release of proapoptotic 
proteins such as cytochrome c and SMAC/DIABLO, containing space to the 
cytosol (Saelens et al. 2004). Cytochrome c is involved the apoptosome 
formation, binding and activating Apaf-1 and procaspase-9 (Chinnaiyan 1999). 
Bcl-2 family proteins control a network of protein interactions that regulate all 
the apoptotic process. In turn, some protein Bcl2 family undergo translational 
modifications (phosphorylation) by enzymes that play an important role in the 
regulation of apoptosis. The family of MAP (Mitogen-Activated Protein) kinase 
are a good example: in this family there are protein with both antiapoptotic 
kinase enzymatic function (ERK, extracellular signal regulated kinase) and 
proapoptotic as JNK kinase (JUN-KINASE) or p38MAPK. The ERK are 
preferentially activated by a mitogen stimulation (Matsuda et al. 1998), while 
JNK and p38 MAPK are activated by stimuli as oxidative stress, hypoxia 
ischemia due to UV radiation, and various cytokines such as Interleukin-1 (IL-
1) and tumor necrosis factor-α (TNF-α) [Raingeaud et al. 1995]. Literature data 
show that because of cellular stress, p38 MAPK activity is associated with the 
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apoptotic intrinsic pathway induction (Ghatan et al. 2000) and one of the 
molecular mechanisms is the phosphorylation of two Bcl-2 family proteins, Bcl2 
and Bax (Rosini et al. 2000), a very important event in maintaining 
mitochondrial membrane integrity. Conformational changes of these two 
proteins alter their function and allow the release of cytochrome c (Mandal et al. 
2008). The inhibition of phosphorylation of p38MAPK is a key event in trophic 
function of neurotrophins.  
 
 
Map kinase 
The MAPK (Mitogen-Activated Protein Kinase) are a family of serine/threonine 
kinase activity enzymes that can regulate the functional activity of target proteins 
and control fundamental cellular processes as development, proliferation, 
differentiation, survival, response to stress and apoptosis. MAPK activity target 
proteins are present in all subcellular compartments, including nuclear. They are 
very heterogeneous molecular and functional point of view (kinases, 
phosphatases, transcription factors, transcription, chromatin structure regulator 
suppressors).  
So far, it has been described four distinct pathways of MAPK: ERK1/2 kinases 
way (extracellular signal-regulated kinase) and ERK5, p38 MAPK and JNK. 
ERK1/2 pathway is typically activated by G-protein coupled receptors or 
activation with intracellular tyrosine kinase domain. ERK 1/2 activation is 
therefore common occurrence of molecular pathways activated by growth 
factors, hormones and inflammatory cytokines. p38 MAPK and JNK is activated 
in response to stimuli, intracellular, such that both extracellular growth factors, 
cytokines, microbial substances (LPS, viral proteins, etc.) and products of 
cellular stress such as oxygen free radicals. 
MAPK activities and functions are finely regulated by tyrosine and threonine 
residues phosphorylation/dephosphorylation: these residues are highly 
preserved in Thr-Xaa-Tyr pattern, typical in dual specificity kinase MAPKK 
family (Wancket et al. 2012). Each MAPK differs from the other members of the 
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family for the amino acid present in the Xaa position (Su and Karin 1996). 
Phosphatases that regulate the phosphorylation and activity of MAPK belong to 
the superfamily protein tyrosine phosphatase (PTP). 
In humans, the PTP are divided into four classes, based on amino acid sequence 
of the catalytic domain. The PTP class I proteins are classified as PTP Dual 
specificity tyrosine-specific phosphatase (DUSP).  
 
MKP-1, a DUSP subfamily member 
One of DUSP subfamily are the MAPK phosphatases (MKP). Targets of MKP 
family activity are the "consensus sequence" Thr-Xaa-Tyr in phosphorylated 
MAPK. The MKP can have specificity for one or several MAPK and the 
expression of certain MKP may be modulated significantly by extracellular 
signals (growth factors, cytokines or LPS) or from micro-environmental 
conditions (as could be a stressed environment). 
Among family members DUSP, MKP1 is one of the most involved phosphatase 
in apoptosis inhibition activated by cellular stress. 
MKP-1 has been originally described as a non-receptor tyrosine phosphatase 
induced by growth factors or by cellular stress. Many evidences show that MKP-
1 preferentially dephosphorylates p38 MAPK and JNK (Franklin and Kraft 
1997), although his task doesn't seem restricted to only these two 
proteins. (Boutros et al. 2008, Shipp et al. 2010). 
Structurally, MKP-1 contains a highly conserved catalytic unit and 
Cdc25/rhodanese homology domain, that includes the KIM pattern (53-55 Arg) 
involved in substrate specificity (Kwak et al. 1994). N-terminal fragment 
contains a nuclear localization sequence, while the phosphatase catalytic domain 
is located near the C-terminal end. 
The expression of DUSP1 gene, coding for MKP-1 human, increases in response 
to LPS, cytokines, growth factors, but also in response to cellular stress factors 
such as hypoxia and thermal shock (Zhang et al. 2012). MKP-1 promoter 
contains not only CRE elements (cAMP responsive elements), E-Box, GRE 
(glucocorticoid responsive elements), VDRE (vitamin D receptor responsive 
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element), but also binding sites for transcription factors (Ryser et al. 2004, Wang 
et al. 2008) that are able in modulating expression (Ryser et al. 2001). 
The stability of the protein is regulated by the function of ERK1/2 through 
phosphorylation on residues Ser-359 and Ser-364, which prevents the 
proteasome-mediated degradation (Scimeca et al. 1997). 
 
 
Functional mimetics of neurotrophins acting at Trk receptors 
Despite the therapeutical potential that neurotrophins could have, their peptidic 
nature gives them drawbacks typical of polypeptides applied as drug. Taken 
together, in vivo instability, activation of undesired pathways, the difficulty in 
crossing the blood brain barrier, a weak diffusion and their vulnerability to 
proteases draw a picture that leads to renounce to their usage as drugs (Poduslo 
et al., 1996). Anyway, a good way to exploit their potential as drugs can be given 
by synthetizing smaller molecules that have chains useful to mimic peptides, as 
the peptidomimetic could be. As well as of lack of immunogenicity, low 
molecular mass and good pharmacokinetic, peptidomimetic are cheaper than 
peptide. (Saragovi et al. 1992) 
As reviewed by Skaper, structure based alignment was performed to have a wide 
idea about the effector and activating site of NGF, BDNF and NT-3. The most 
used strategy was to enrich small molecules with functional chains useful to bind 
Trk family receptors. Based on this idea, several compounds were developed, 
trying to find the so-called “hot spots” at ligand-receptor surfaces, that resulted 
to be mostly constituted by β-turn conformations (Skaper 2011). 
As a matter of fact, LeSauteur et al developed a mimetic antagonist of NGF, a 
beta-loop NGF monomeric cyclic peptide analogs able to block the signal 
triggered by TrkA (LeSauteur et al. 1995). Further studies based on mimicry 
concept of pre-existent NGF-mimetics, (Zaccaro et al. 2005), developed a library 
of small molecules peptidomimetics and agonist of TrkA and TrkC, basing the 
chains structure on β-turns of NT-3 and NGF. 
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More recently, a novel compound, called MT2, was selected among over one 
hundred molecules with bicyclic three-dimensional scaffold, taking into account 
the spatial conformation of the binding site for NGF in TrkA and their affinity 
for the NGF receptor. 
 
MT2 
MT2 is a patented non-peptidic compound and NGF-mimetic (Figure 7). It is the 
result of a selection from a chemical library based on the study of NGF receptor, 
and in particular its active domain, TrkA- domain 5 (TrkA-d5). In fact, Scarpi et 
al. took in consideration the spatial conformation of the binding site of NGF and 
TrkA and selected only molecules that could fit in the domain 5 of receptor. 
From the in vitro dose-dependent effect experiments on PC12 cells, MT2 
resulted the compound with the highest NGF-like activity of four compounds.  
In serum deprivation conditions, it has been demonstrated that MT2 lead to the 
same NGF-TrkA bound effects, increasing phosphorylation of ERK1/2 and Akt 
proteins and production of MKP-1 phosphatase, modulating p38 mitogen-
activated protein kinase activation. It has also been demonstrated that corrects 
biochemical abnormalities and maintains cell survival in vitro model of 
Alzheimer's disease (AD) based on NGF deprivation of rat hippocampal 
neurons. (Scarpi et al. 2012) The drug is also able to counteract the onset of toxin 
induced dopaminergic neuronal cell death and synaptic alterations in in vitro 
models of Parkinson disease (PD) (data not shown). 
Thanks to its non-peptidic nature and small dimensions, MT2 has a favored 
pharmacokinetic if compared to a grow factor, being able to cross the blood brain 
barrier (BBB) and not being attacked by proteases. 
 
Figure 7. Structural formula of MT2 (Scarpi et al., 2012) 
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Aims 
 Aims 
 
MT2 is a novel compound, kindly given by laboratory of Prof. Cozzolino, that 
showed to be able to bind TrkA and TrkB, mimicking the effect of the NGF and 
BDNF (Scarpi et al. 2012). Unlike growth factors, MT2 can exploit a better 
pharmacokinetic, with a better half-life and a potential efficacy due to its better 
diffusion through blood brain barrier than a polypeptide. MT2 showed to activate 
the same pathway driven by the bound between NGF and TrkA the anti-apoptotic 
pathway in condition of starvation (deprivation of growth factor). Binding the 
domain-5 of TrkA (TrkA-d5), MT2 triggers the survival pathway through 
activation of ERK1/2 and p-Akt proteins and production of MKP-1 phosphatase, 
modulating the p38 mitogen-activated protein kinase activation.  
Principal aim of our work was to test efficacy of MT2 treatment on 
inflammatory, neurodegenerative damage in central nervous system. 
Furthermore, we wanted to dissect MT2 mechanism of action investigating its 
role in nervous tissue protection and repair together with the possible modulation 
of immune response.  
To achieve this aim we exploit three different experimental models: 
- Mouse organotypic spinal cord culture challenged with a 
proinflammatory cytokines cocktail, this model permitted us the study of 
in vitro CNS microenvironment and synaptic function during the early 
phases of inflammation. 
- MOG induced experimental autoimmune encephalomyelitis in C57Bl/6 
mice. We analyzed MT2 protective effects on neuronal tissue and on 
autoimmune reaction during acute and chronic phases of the disease.  
- Cuprizone induced demyelination in C57Bl/6 mice. We investigated 
MT2 treatment effects during toxic demyelination, in order to isolate 
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demyelinating events from immune reaction, mimicking late 
neurodegenerative phases of MS. 
-  
  
Methods 
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Methods 
 
Animals 
In the present work Experimental autoimmune encephalomyelitis (EAE) was 
induced in 6 weeks-old female C57BL/6 mice (a total of 18, obtained from 
ENVIGO RMS s.r.l., Italy), both for acute and chronic phase of disease. We also 
used this strain for Cuprizone model.  Animals had a mean of   ̴20 gr weight were 
kept in a standard housing condition, with a light/dark cycle of 12 h (08.00–20.00 
hours), at temperature of 23°C and free access to food and water. Animals were 
usually subdivided in 4-5 animals per cage. 
 
MOG35-55-induced EAE in C57BL/6 mice 
Active EAE was induced in 6-weeks-old female mice through an active MOG35-
55 peptide emulsion immunization strategy. Emulsion subcutaneous injections 
are composed by 1:1 ratio of MOG35-55 peptide 
(MEVGWYRSPFSRVVHLYRNGK, EPK1, 5 mg, purity >85%; Espikem, 
Florence, Italy) and Mycobacterium Tuberculosis (prod. #231141, BD Difco, 
Detroit, MI) in Incomplete Freund's Adjuvant (IFA – Sigma Aldrich F5881). 
MOG35-55 was diluted in ddH2O to a final concentration of 1,33 mg/ml; 
Mycobacterium Tuberculosis was added to CFA, obtaining a final 4 mg/mL 
concentration. 100 µl of antigen/CFA emulsion was injected subcutaneously into 
two different sites on each hind flank; another injection was performed closer to 
the base of the tail; Bordetella Pertussis Toxin (PTX - 516560-50UG) was 
administered by intraperitoneal (ip) injections on days 0 and 2 post immunization 
(days post immunization, dpi). (Hofstetter et al. 2002) Food and water were 
available ad libitum, and mice were weighed daily. 
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EAE’s clinical course assessment 
 
Mice’s clinical course was judged daily, giving them an assessment as following 
(Figure 8): 0, no detectable signs; 0.5, partial limp tail; 1, complete limp tail; 1.5, 
limp tail with hind limb weakness or gait abnormality; 2, limp tail with unilateral 
hind limb paralysis; 3, bilateral hind limb paralysis; 4, bilateral hind limb 
paralysis and forelimb weakness; and 5, bilateral forelimb and hind limb 
paralysis (endpoint). Furthermore, animal’s weights were daily evaluated. 
 
 
Figure 8.  Schematic representation of EAE severity assessment. Clinical signs of the EAE are 
assessed with a grading scale with an arbitrary score of 0 to 5. 
 
Cuprizone model 
 
Cuprizone model allowed us to investigate of remyelinating mechanisms in 
young adolescent animals following toxin-induced 
demyelination. Demyelination was induced by 0.2% cuprizone [N,N'-
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bis(cyclohexylideneamino)oxamide; Sigma-Aldrich] into the food over a period 
of 35 days starting on day 0 to day 35. Food and water were available ad libitum. 
In this experiment were used 7 mice for vehicle; 8 mice for treated group. In 
detail: 7 mice (3 for vehicle and 4 for treated group) were sacrificed at 49th day 
during demyelination phase, 8 mice (4 for each group) were sacrificed at 56th day 
during remyelinating phase. 
MT2 treatment 
 
MT2 (Figure 9) is a NGF mimetic molecule, MT2 that is a patented non-peptide 
compound, agonist of the high affinity Nerve Growth Factor Receptor (NGFR) 
Tropomyosin receptor kinase A (TrkA) and of TrkB. Mice were treated daily, 2 
mg/Kg per mice through intraperitoneal injections, 150 µL. MT2 is solved in a 
9% ethanol solution. 
In EAE experiments, mice were treated for 10 days both acute phase and chronic 
phase. For the acute phase treatment, we started treatment from 14 dpi, when 
usually EAE acute phase starts (Figure 10A), ending administration at day 23 dpi. 
Treatment during chronic phase of disease was experimented treating animals 
with MT2 or vehicle from 22 dpi to 31 dpi. During cuprizone experiments, MT2 
was given daily from day 21 to day 42 (Figure 10B). During both experiments, 
vehicle mice received i.p. the solution without drug in the same period of treated 
ones. 
Figure 9. The MT2 structure (Scarpi et al., 2012) 
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After the mice were sacrificed, lymph nodes, spleens, spinal cords and brains 
were collected.  
Cells isolation from lymphoid and CNS organs 
 
Isolation of cells from lymph node and spleen 
Cells were isolated from the cervical and drainage lymph nodes or spleen by 
mechanical dissociation of the tissues by using sterile nylon filters with 70 μm 
pore (BD Falcon). Cells derived from spleen were, subsequently, separated by 
centrifugation in Ficoll gradient (Biochrom AG) obtaining the mononucleated 
fraction (MNCs). 
Figure 10. MT2 treatment during EAE and cuprizone experiments. Experimental scheme of acute (A) 
and chronic (B) EAE with 10-days MT2 treatment scheduling. (C) shows the experimental course 
of MT2 treatment during Cuprizone model. 
A 
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Isolation of cells from nervous system 
Spinal cord and cerebellum were directly lysed with Collagenase (5 mg/ml, 
Sigma Aldrich) for 15 minutes at 37°C. Tissues were then mechanically 
dissociated by sterile Falcon™ Cell Strainers with nylon mesh with 70 µm 
micron pores (Fisher Scientific). Cells were separated by centrifugation in 
Percoll gradient (Biocoll) following the manufacturer instruction. 
 
Ex-vivo proliferation test of specific antigen cells 
Cells isolated from the lymph nodes or spleen were distributed in 96-well plates 
at a concentration of 1,5x105 cells / 200 μl / well in the presence or absence of 
peptide MOG35-55 (10 or 50 μg/ml). Cells were cultured for 72h at 37° C in a 
humidified atmosphere containing 5% CO2. After this incubation time, 1 μCi of 
3H-Timidine (PerkinElmer) was added to each well. Cells were then collected 
on glass fiber filters using the appropriate Cell Harvester instrument (Mach III 
Cell Harvester, Tomtec, Inc.). Thymidine incorporation was measured as count 
per minute (cpm) using the MicroBeta® TriLux 1450 (Wallac) radiation counter. 
The extent of proliferative response was expressed as a stimulation index (SI): 
SI=
cpm of cultured cultures
cpm of non-stimulated cultures
.  
Cytokines assay 
For treated-MT2 group and vehicle one (4 or 3 mice for each experimental 
setting) cells isolated from lymph-node or spleen were plated (1 x 105 cell/well) 
and activated or not with MOG35-55 for 72 h. Supernatants were collected and 
stored at -20°C for determination of IL-10, IL-4, IL-6, IL-17, IFN-γ, TNF-α, 
CXCL1, CXCL2 and CXCL10 through Bio-Plex® Multiplex Immunoassay 
System assay (Bio-Rad) using ProcartaPlex kit (Thermo Fisher). This technique 
involves the use of the multiplex immunoassay that enables the simultaneous 
detection and quantification of different biomolecules. Bio-Plex apparatus 
allows the multiplex analysis, according to manufacturer’s recommendations. 
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Flow cytometry analysis 
Phenotype analysis focused on the characterization of dendritic cells (DC) and T 
cells producing IFN-γ or IL10. For DC and T cells characterization cells were 
isolated from lymph node. For IFN-γ and IL10 production analysis, cells were 
isolated from spinal cord. After isolation from the lymph nodes, cells were 
suspended in PBS containing 0.05% BSA (bovine serum albumin) and EDTA 2 
mM, counted and subdivided into 1x105 cells each. Cell suspensions were 
labelled with fluorescent monoclonal antibodies, specific for membrane 
molecules expressed by DCs and T cells. Cells were incubated for 15 minutes in 
the dark and at room temperature with the following fluorescent monoclonal 
antibodies: CD3 FITC (1:100), IL-10 APC (1:100) and IFN-gamma PE (1:100).  
(eBioscience). Subsequently, cells were washed and suspended in 500 μl of PBS. 
Cells were then analyzed by flow cytometry. Simultaneously cells were isolated 
from spinal cord and cerebellum with Percoll gradient solution (Biocoll) and 
labelled with fluorescent monoclonal antibody, specific to membrane molecules 
expressed by T cells. The cells were incubated for 15 minutes in the dark and at 
room temperature with CD3 FITC (1:100) (eBioscience). Then, cells were 
washed and fixed with formaldehyde 0,01% (SIGMA) for 20 minutes. After the 
incubation time cells were washed and left overnight at 4° C. The day after 
membranes were disrupted using Saponin (0.5% in PBS) permeabilization 
buffer, enable antibodies to go through pores without dissolving plasma 
membrane. Follow antibody staining: IFN-γ and IL10 (eBioscience) antibodies 
were prepared in permeabilization buffer to keep cells permeable. For the 
detection of secreted proteins Brefeldin (R&D System) was added to antibodies 
mixture, preventing protein release from the Golgi apparatus and enabling the 
detection of cells expressing the protein. 
As last step cells were ready for flow cytometry analysis by a 4-color 
Cytofluorimeter with Argon 488 nm laser (Partec). 
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Histopathology  
Spinal cords and brains were fixed in 4% paraformaldehyde for 48h, washed in 
PBS, dehydrated with a growing alcohol concentration and xilen, changing every 
solution twice. Last step was to embed organs in paraffin. 5 µm-cross sections 
were then stained to evaluate the presence of inflammatory infiltrates, 
demyelination and axonal loss. Pictures were taken with Olympus BX40 
(Olympus, Milano, Italy). 
 
Hematoxylin and eosin stain 
To detect the presence of inflammatory infiltrates, slides with spinal cord 
samples were stained with hematoxylin-eosin (HE). Hematoxylin is a basic dye 
that stains in purple blue the negatively charged cellular components such as 
nucleic acids, membrane proteins and cell membranes that are thus called 
basophils. Eosin is a stain contrast agent of hematoxylin. It stains basic 
components loaded positively like many cellular proteins, mitochondrial 
proteins and collagen fibers that are thus called eosinophils or acidophilic. 
Binding these components, it gives dark red or pink and it is used in histology 
for staining cytoplasm.  
The staining protocol provides the following steps: 
- Samples were de-paraffined in xylene (6' for 2 times); 
- Samples were rehydrated by a decreasing sequence of alcohols: 100% 
ethanol (3', 3 times), 95% (3') ethanol, 75% (3') ethanol, distilled H2O; 
- At this point the samples were stained: haematoxylin (2'), current H2O 
(10'), eosin (20-30”); 
- The samples were rinsed in running water and dehydrated by means of 
an ascending alcohol sequence: 75% (3') ethanol, 95% (3') ethanol, 100% 
(3') ethanol, xylene (3') 
- Slides are fitted with a drop of upright balm and the slide covers the 
object, then dry in the stove. 
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Luxol fast blue stain 
 
Luxol fast blue (LFB) is a chemically derived dye-tetrabenzotetrazo-porphyrin 
dye, which is used in histology for myelin colouring, allowing to evaluate the 
extent of demyelination. The selective affinity of porphyrins for myelin has been 
demonstrated and the electivity of the dye for the central nervous system is 
mainly due to the bonds that form with phospholipid structures such as lecithin 
and sphingomyelin. 
The staining steps are as follows: 
- xylene 15’ for 2 times 
- ethanol 4’ for 2 times 
- Luxol Fast Blue 0,1% overnight at 50-60° C (Prepared by solubilizing 
0,50 g of the Luxol Fast Blue powder in 0,5 l of absolute ethanol and 
adding 2,5 ml of glacial acetic acid) 
- in distilled H2O washing 15” lithium carbonate 
- ethanol 70% 30'' for 2 times 
- in distilled H2O washing 
- Periodic acid 0,8% 10” 
- in distilled H2O washing Schiff reagent (at room temperature) 20’  
- washing solution 2’ for 3 times (Consisting of: 20 ml of 10% potassium 
bisulfite, 5 ml of 37% HCL and 500 ml of distilled water) 
- water running in the running water 15’  
- ethanol 50% 1’ for 2 times 
- ethanol 100% 1’ for 3 times 
- butylacetate/xylene 1’ for 2 times 
Furthermore, two operators blindly evaluated infiltrates through a 
semiquantitative method: we adopted a specific assessment, giving score 0 for 
no infiltration, score 1 for foci of subarachnoid cell infiltration, score 2 for 
subarachnoid infiltration, score 3 for foci of parenchymal infiltration, score 4 for 
diffuse and widespread parenchymal infiltrates. As well, we performed a 
demyelination assessment through Luxol Fast Blue staining, judging with a 
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score of 0 no demyelination; 1 refers to foci of demyelination that is superficial 
and proximal to the subarachnoid space and that involves less than 25% of the 
lateral columns; 2 represents foci of deep parenchymal demyelination and that 
involves over 25% of the lateral columns; while a score of 3 denotes diffuse and 
widespread demyelination. (Giuliani et al. 2005) 
 
Bielschowsky stain 
The Bielschowsky technique is a silver staining method used in histochemistry 
for the visualization of nerve fibers. It includes these following steps: 
1. Deparaffinize and hydrate sections to dH2O.  Wash 3 times for 3 min. in dH2O. 
2. Place sections in 50 ml 10% silver nitrate in dark at 37ºC for 30 min. Keep this 
solution after incubation (for use in step 4). 
3. Wash 3X for 3 min in dH2O. 
4. Add concentrated ammonium hydroxide dropwise with stirring to the silver 
nitrate solution reserved from step 2. Add only enough to dissolve the dark initial 
precipitate but not more. 
5. Incubate sections in this solution for 15 min at 37° C. Again, save this solution 
for use in step 6. 
6. Wash sections in 0.1% ammonium hydroxide 3X for 2 min at room temperature. 
7. Add 350 μl developer solution (0.2 ml 37% formaldehyde, 12 ml dH2O, 12.5 μl 
20% nitric acid and 0.05 g citric acid) to the silver hydroxide solution saved from 
step 4. 
8. Stain sections in this solution for 10 min until they turn black. 
9. Wash in 0.1% ammonium hydroxide 3X for 2 min and dH2O 3X for 2 min. 
10. Tone in 0.2% gold chloride for 5 min. 
11. Fix in 5% sodium thiosulfate for 1 min. 
12. Wash in dH2O, dehydrate in alcohols then xylene and mount. 
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Immuno-fluorescence on paraffin sections 
In 5 µm-cross sections paraffin was removed by xylene, absolute ethanol and 95% 
ethanol, then rinsed in distilled water. Slices were imaged using a Leica DM6000B 
microscope with appropriate excitation and emission filters for each fluorophore was 
used to acquire representative images. The slice details were imaged at 4x 
magnification. The analyses were then performed using the ImageJ software 
(http://rsbweb.nih.gov/ij/).  
De-waxing and dehydration steps were followed by a step of blocking for non-
specific staining between the primary antibodies and the tissue, by incubating in 
blocking buffer (1% horse serum in PBS) for 30 minutes at RT. 
Spinal cords and brains sections were incubated with primary antibodies overnight, 
4°C. Primary antibodies used are: mouse monoclonal anti-glial fibrillary acidic 
protein, GFAP (Sigma G3893, 1:200 dilution); Anti-Myelin Basic Protein Antibody, 
MBP (Millipore MAB386, clone 12, 1:100); Anti-Iba1 (Wako, cat. #019-19741). 
Subsequently slices were washed 3 times with PBS and incubated with secondary 
antibodies for 2h at RT.  
The secondary antibodies we used are: Alexa 488 donkey anti-rat (Invitrogen 
A21208, 1:200 dilution); Alexa 635 goat anti-mouse (Thermo Fisher A31574, 1:400 
dilution); Alexa 488 goat anti-rabbit (Thermo Fisher A11008, 1:400 dilution. 
 
 
 
Immunohistochemistry on PFA-fixed cells 
Cells were seeded (105 cells/spot) on positive charged glass slides, fixed with PFA 
4% (Bioptica) 15 minutes at room temperature, then washed with PBS and 
permeabilized with PBS/FBS 5%/Triton 0.3% solution for 30’ RT in the dark. TrkA 
(1:300), TrkB (1:300) CD3 (1:400) CD4 (1:300) were diluted in permeabilization 
solution and slides immunostained drop by drop overnight a 4°C. The day after, after 
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three washes, we added the secondary antibodies diluted in permeabilizing solution 
for 2 hours at room temperature.  Slides were then washed three times in PBS and 
closed with Prolong Diamond mounting medium containing DAPI (Life 
Technologies). Once dried, slides were observed at a fluorescence microscope 
(Olympus BX600, Japan). For each slide we analyzed four fields, 6 slides per groups, 
vehicle and MT2-treated each. 
 
Transmission electron microscopy 
After sacrifices, brains were taken from animals and fixed in Karnovsky solution 
(paraformaldehyde 2.0 gm, 1M sodium hydroxide 2 - 4 drops, 50% glutaraldehyde 
5.0 ml (25% glut - 10 ml), 0.2M cacodylate buffer, pH 7.4.), then 3 mm section were 
first dehydrated, then embedded on Epon 812 Luft resin. 60-70 um sections were 
stained with uranyl-acetate and bismuth, then view with JEM 1010 electron 
microscope (Jeol, Tokyo, Japan) at 80 kV and acquired by MegaView III (Soft Image 
System Gmbh, Germany). 
 
 
 
 
SDS-PAGE and Western-Blot 
At the days of sacrifice, a piece of spinal cord were stocked in a tube containing RIPA 
buffer 1x (50 mM Tris-HCl, pH 7.4; 150 mM NaCl; 2 mM EDTA; 1 mM NaF; 1 mM 
sodium orthovanadate, 1% NP-40) in the presence of phosphatase inhibitor cocktail 
2 and 3, protease inhibitor cocktail (Sigma Aldrich), then stocked at -20°C. At the 
moment of experiment, samples were thaw on ice, added stainless steel beads in the 
tubes and then mechanically lysed through Tissue Lyser (Qiagen). Samples were 
lysed after 2 cycles, with an oscillation frequency of 30 Hz.  Lysed samples has been 
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recovered and centrifuged at 13000 rpm at 4°C for 15 minutes, then upper phase 
containing proteins was collected.  After proteins quantification through Pierce™ 
BCA Protein Assay Kit (Thermo Scientific) in order to load 35-40 ug of proteins onto 
SDS-PAGE. Subsequently hand-casted 12% Sodium Dodecyl Sulphate-
PolyAcrylamide Gel Electrophoresis polyacrylamide (SDS-PAGE) was prepared 
following Bio-Rad protocol. Gel was included in specific support for electrophoresis 
system that was assembled in the specific tank. Once filled with running buffer (TBA 
10% in PBS), 35-40 µg of samples were loaded onto gel wells and ran at constant 
voltage of 200 V for 60 minutes. After proteins separation, gel was blotted onto 
methanol-activated nitrocellulose filters (GE Healthcare, Fairfield, CT, USA). After 
a 15 seconds-treatment, nitrocellulose filters were rinsed in ddH2O for 1 minute and 
then immersed in transfer buffer. In order to transfer proteins, a sandwich made by 
sponges/Whatman cellulose filter paper (GE Healthcare Life 
Sciences)/gel/nitrocellulose/Whatman cellulose filter paper/sponges was made and 
used in the blotting system filled with transfer buffer. Transferring operation lasted 
overnight at room temperature at constant voltage of 100 V.  Once transferred, 
membrane with proteins was washed with PBS-Tween 0,05% and then stained with 
Ponceau solution to verify the correct protein transfer. Nitrocellulose membrane is 
then incubated for 1 hour with BSA 3% in PBS for blocking. 
PVDF membrane is then incubated overnight with primary antibodies in a 3% 
BSA in PBS solution, keeping it on a shaker at 4°C.   
Following primary antibodies were used: 
 Rabbit anti-MKP-1 1:1000 dilution, 
 Rabbit anti-P-p38 1:1000 dilution, 
 Mouse anti-α-Tubulin 1:2000 dilution. 
After overnight incubation, membrane was washed 3 times for 5 minutes with 
PBS-Tween, and immediately afterwards it was incubated in agitation for 1 hour at 
room temperature with secondary antibodies conjugated with horseradish peroxidase. 
This last incubation was followed by another 3 astir washes of 5 minutes with PBS-
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Tween 0,1%. Washes are made for the purpose of removing antibodies bound not 
specifically that could give fake positive signals. 
Secondary antibodies are: 
 Anti-rabbit for MKP-1 e P-p38, dilution 1:10000; 
 Anti-mouse α-tubulin, 1:10000. 
Chemiluminescence was revelated through Chemidoc (Biorad) machinery, using 
Luminata Forte Western HRP (Merck) as substrate for horseradish peroxidase. 
 
 
Organotypic culture preparation 
 
See attached manuscript draft.
   
Results 
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Results 
Organotypic culture 
See paper in press on Molecular Brain Journal titled: “Neuroinflammation and 
synaptopathy: bridging pro-inflammatory signals, synaptic transmission and 
protection in spinal motor circuits in vitro”  by Medelin M, Giacco V, Aldinucci 
A, Sibilla A, Bonechi E, Ballerini L, Cozzolino F and Ballerini C. The submitted 
document is attached to thesis.  
 
Effect of MT2 treatment on preclinical, acute and 
chronic phase of EAE 
Given the neuroprotective and anti-inflammatory role of NGF, we tested the 
possible therapeutic effect of our NGF mimetic molecule MT2 on EAE, treating 
MOG 35-55 immunized C57Bl/6 mice both during the acute and the chronic phase 
of the disease. 
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MT2 treatment during the acute phase of EAE  
Effect of MT2 on EAE clinical course 
 
 
First, we investigated the effect of MT2 treatment during the acute phase of EAE, 
that usually arise at 14 dpi. We treated animals from 14 to 23 dpi, monitoring 
clinical score and body weight trend daily. We treated a total of 18 animals per 
group (MT2 and vehicle), in independent experiments. As reported in Figure 11, 
we found that MT2 significantly (***p=0,005) improved the clinical score 
(1,42±0,12 vs 2,18±0,2, mean±SEM) and body weight (21,34±0,15 vs 20,45±0,185 
gr). 
 
Histopathological analysis of spinal cord  
The therapeutic effect of MT2 on EAE was verified through histopathological 
analysis of spinal cord samples from mice sacrificed at 26 dpi: we evaluated the 
number of immune cell infiltrates, the degree of demyelination and the axonal 
loss, by hematoxylin and eosin (H&E), Luxol Fast Blue (LFB) and 
Bielschowsky stains, respectively (Figure 12A, 12B and 12C). 
Figure 11. MT2 treatment of EAE mice during acute phase of the disease: effect on clinical score and body weight. 
Animals (N=9 per group, two independent experiments) were treated with MT2 or vehicle from 14 dpi (treatment period 
is highlighted in pale blue in graphs A and B. A) clinical score (mean values±SEM of two independent experiments, 9 
animals/ group each) of treated animals (orange curve) and controls (green curve) (***p=0,005, unpaired t-test). B) 
Body weight trend (mean values±SEM of two independent experiments, 9 animals/group each) of treated animals 
(orange curve) and controls (green curve) (****p=0,0007, unpaired t-test). 
  
59 
 
The semiquantitative analysis of the number of immune infiltrates, marked with 
HE staining (Figure 12A, arrows) showed a significant (****p<0,0001) reduction 
of the number of infiltrates foci in MT2 samples with respect to controls 
(0,85±0,18 vs 3,81±0,20, mean±SEM) (Figure 12D), corresponding to a higher 
histological score (Figure 12E) in vehicle mice (1,2±0,07, mean±SEM) than in 
treated group (0,375±0,06, mean±SEM).  
Then we evaluated the extent of demyelination on treated and control mice 
through LFB staining (Figure 12B). Semiquantitative analysis of demyelination 
showed that MT2 significantly (****p<0,0001) reduces the number of 
demyelination areas (0,34±0,08 vs 3,94±0,19, Figure 12F) and the demyelination 
score (0,40±0,08 vs 1,65±0,11, G).  
Bielschowsky staining (Figure 12C) proves that axonal loss is widely present in 
controls (arrows), but not detectable in treated mice. Since HE, LFB and 
Bielschowsky staining were performed on consecutive slices (as described in 
Methods), we found a “geographic” match between presence of infiltration foci, 
demyelinated areas and axonal loss. 
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Figure 12. Histopathological evaluation of spinal cord of EAE mice treated with MT2 during the acute phase of the 
disease. A) Haematoxylin and Eosin (HE), B) Luxol Fast Blue (LFB) and C) Bielschowsky staining of paraffin 
embedded spinal cord slices (5µm), of EAE mice treated with MT2 compared to controls (vehicle), to evaluate the 
presence of inflammatory infiltrates, demyelination and axonal loss, respectively. D-G) Semiquantitative evaluation of 
number of infiltration foci (D), infiltrates score (E), number of demyelination areas (F), demyelination score (G); each 
column in graphs represents the mean value±SEM of 6 animals. 
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As shown in Figure 13, the spatial correspondence between the presence of 
infiltrates (HE) and lack of myelin (LFB), evident in control mice (upper panel) 
and almost absent in MT2 treated ones (lower panel), was confirmed by 
immunofluorescence labelling of myelin basic protein (MBP).  
 
MT2 ability on mimicking classical NGF anti-apoptotic pathway in 
CNS 
To understand if the beneficial effect of MT2 on EAE pathology could be exerted 
on CNS cells through its known anti-apoptotic function via TrkA receptor 
(Scarpi et al. 2012), we investigated the expression of proteins involved in TrKA 
mediated anti-apoptotic pathway. Experiments were performed on spinal cord 
homogenates by western blot techniques.  
As shown in Figure 14, we observed a trend towards an increased MKP-1 
expression in MT2-treated animals compared to controls (2,4±0,28 vs 1,4±0,28 
ratio MKP-1/β-actin - 15A), accompanied by a decreased level of phosphorylated 
p-38 (0,79±0,26 vs 2,29±0,81 ratio p-p38/α-tubulin- 15B). Consistently with 
Figure 13. Histological analysis of immune infiltrates and demyelination in spinal cord of EAE mice treated 
with MT2 during the acute phase of the disease.  Infiltrates were detected by Haematoxilin/Eosin staining 
(H&E); Luxol Fast Blue/cresyl violet staining (LFB) and MBP immunofluorescence labelling were used to 
visualize myelin. Upper panel: EAE animals treated with vehicle (CTRL); lower panel: EAE mice treated 
with MT2 (MT2). Red squares in the upper panel show the correspondence between the presence of 
infiltrates and lack of myelin. 
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these findings, we observed a trend towards an increased expression of Pro-
caspase-3 (15C) in MT2 treated mice compared to controls (0,56±0,26 vs 
0,17±0,11 Procaspase/α-tubulin).   
 
The same samples were analyzed for the expression of the inflammatory marker 
inducible nitric oxide synthases (iNOS) (Figure 15). We didn’t detect any 
Figure 15. Effect of MT2 treatment during EAE acute phase on iNOS expression in CNS. A) Western blot analysis 
of iNOS expression in spinal cord samples of mice treated with MT2 (orange) or vehicle (green) during the acute 
phase of the disease and sacrificed at 26 dpi. α-tubulin: housekeeping protein. Each lane represents a single sample. 
One experiment representative of 3 independent ones. B) Densitometric analysis of iNOS expression: graph shows 
the ratio between iNOS and α-tubulin optical density (mean value±SEM of 3 experiments). 
Figure 14. Effect of MT2 treatment during EAE acute phase on NGF anti-apoptotic pathway in CNS.  Upper 
panel: Western blot analysis of MKP-1, P-p38 and Pro-caspase 3 expression in spinal cord samples of mice 
treated with MT2 (orange) or vehicle (green) during the acute phase of the disease and sacrificed at 26 dpi. 
Actin and α-tubulin were used as housekeeping proteins. Each lane represents a single sample. Here we 
show one experiment representative of 3 independent ones. A-C) Densitometric analysis of MKP-1 (A), P-
p38 (B) and Pro-caspase 3 (C) expression reported as ratio versus the optical density of the corresponding 
housekeeping protein. Each column in the graphs report mean value±SEM of 3 experiments. Green columns: 
vehicle treated mice (controls):  orange columns: MT2 treated mice. 
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significant variation about iNOS production between MT2 and vehicle treated 
mice. 
Effect of MT2 treatment on immune response  
We investigated the possible effect of MT2 on ex vivo immune cells collected 
from lymph nodes, evaluating MOG35-55-driven proliferation and cytokine 
production. For this purpose, cells were stimulated with MOG35-55: results 
showed that treatment with MT2 didn’t modify the proliferative response of 
lymphoid cells to the antigen (Figure 16). Afterwards, we assessed the presence 
of cytokines of inflammatory response in supernatant of MOG35-55-stimulated 
cells assaying with LUMINEX technology the level of IFN-γ, TNF-α, IP10, 
MIP2, KC, IL4, IL10, MCP1, IL17 and IL6 (Figure 17). As for proliferative 
response, MT2 didn’t change cytokine profile of MOG35-55 stimulated cells. 
Figure 16. Ex vivo proliferation assay of lymph nodes cells from EAE mice treated during the acute phase of 
the disease. Proliferative response to MOG35-55 peptide of lymph nodes from EAE mice sacrificed at 26 dpi 
upon treatment with MT2 (orange columns) or vehicle (green columns) during the acute phase of the disease. 
Proliferation was tested by 3H-Thymidine incorporation. Left: Δcpm (mean cpm of antigen stimulated cells-
mean cpm of not stimulated cells). Right: stimulation index (SI= mean cpm of antigen stimulated cells/mean 
cpm of not stimulated cells). Mean values±SEM of two independent experiments (N=9 per group). 
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MT2 treatment during the chronic phase of EAE 
1.2.1 Effect of MT2 on EAE clinical course 
We then evaluated the possible MT2 therapeutic efficacy in EAE if administered 
during the chronic phase of the disease. To this aim we treated 12 EAE mice, 6 
Figure 18. MT2 treatment of EAE mice during chronic phase of the disease: effect on clinical score and body 
weight. Animals (N=6 per group) were treated with MT2 or vehicle from 23 to 31 dpi (treatment period is 
highlighted in pale blue in graphs). A) Clinical score (mean values ±SEM, 6 animals/ group) of MT2 treated 
animals (orange curve) and controls (green curve). B) Body weight trend (mean values ±SEM, 6 animals/ 
group) of MT2 treated animals (orange curve) and controls (green curve) (***p=0,0006, unpaired t-test).  
Figure 17. Cytokines quantification on acute phase of EAE from lymph nodes. The inflammation state was 
investigated by LUMINEX technology in supernatant of T-cell line MOG35-55 -immunized. We considered 
IL-6 (A), TNF-α (B), IP10 (C), MIP2 (D), KC (E), IL-4 (F), INF-g (G), MCP1 (H), IL-17 (I), IL.10 (J) as 
immuno-response markers. Measurements were made in 4 different experimental conditions: MOG-
stimulated (CTRL MOG, light green), stimulation with MOG and treated with MT2 (MT2 MOG, green), 
PHA stimulated (CTRL PHA, light orange) and upon MT2 treated and PHA stimulated (orange, MT2 
PHA). The column graphs show total protein levels in supernatant, expressed as mean pg/mL of two 
experiments ± SEM (N=9 animals). ****p < 0,0001 
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with MT2 and 6 with vehicle, from 23 to 31 dpi. 
As shown in Figure 18B, MT2 was able to avoid the body weight drop observed 
in control mice (***p=0,0006). Despite the significant result, the difference in 
body weight that already existed between the two groups prevents the 
determination of whether the effect during treatment is entirely or partially 
operable by MT2. On the other hand, the drug is not effective in modifying the 
clinical score (Figure 18A).  
 
Histological analysis of spinal cord 
The clinical findings were supported by the histological analysis of spinal cord 
isolated at 32 dpi, upon 10 days of MT2 treatment. We evaluated the presence of 
immune cell infiltrates, the degree of demyelination and the axonal loss, by 
hematoxylin and eosin (H&E), Luxol Fast Blue (LFB) and Bielschowsky 
staining, respectively (Figure 19). According to the clinical score observation, 
the histological analysis didn’t reveal any difference between MT2 treated mice 
and controls. 
  
66 
 
 
 
EAE clinical course was further investigated by Rotarod test. Although vehicle 
and MT2 treated animals showed a similar riding time (Figure 20A), in MT2 
group we found a significant (****p<0,0001) lower number of falls during the 
Figure 19. Histopathological evaluation of spinal cord of EAE mice treated with MT2 during the chronic 
phase of the disease. A) Haematoxylin and Eosin (HE), B) Luxol Fast Blue (LFB) and C) Bielschowsky 
staining of paraffin embedded spinal cord slices (5µm), of EAE mice treated with MT2 compared to controls 
(vehicle), to evaluate the presence of inflammatory infiltrates, demyelination and axonal loss, respectively. 
Figure 20. Effect of MT2 treatment during the chronic phase of EAE on motor coordination and balance. 
Animals (N=6 per group), during the treatment period, were daily subjected to a walking of 180 seconds on a 
rotating rod at speed of 30 rpm. In A) we show the average time on Rotarod, Orange curve: MT2 treated mice; 
green curve: controls (mean values±SEM, 6 animals/ group). In B) graph represents the mean number of falls 
during the exercise (mean values±SEM, 6 animals/group each) (****p<0,0001 -Mann-Whitney test). 
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exercise than in controls (1,11±0,08 vs 3,02±0,39 falls, mean±SEM, 6 animals 
per group) (Figure 20B).  
 
MT2 treatment during immunization and preclinical 
phase 
In order to understand if the ability of MT2 to ameliorate the disease course of 
EAE when administered during the acute phase could be due to an anti-
inflammatory effect, we explored the impact of MT2 on immune system during 
active immunization, focusing our attention on T cells. To this end we carried 
out in vivo and in vitro experiments. 
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In vivo treatment of MOG 35-55 immunized mice during the 
preclinical phase of the disease 
First, we decided to treat with MT2 MOG35-55-immunized mice before the onset 
of the clinical signs, from 2 dpi to 13 dpi. At 14 dpi mice were sacrificed and we 
isolated lymphomonocytes from lymphoid organs and spinal cord to characterize 
phenotype and cytokine production of both peripheral and CNS infiltrating T 
cells.  
In particular we evaluated the percentage of T cells producing IFNg or IL10 by 
intracellular staining and flow cytometry analysis. As shown in Figure 21, MT2 
in vivo pre-treatment significantly reduced (*p=0.025, Unpaired t-test) the 
percentage of IFN-γ positive cells in draining lymph nodes (20,87%±3,8% in 
Figure 21. Effect of MT2 treatment during EAE preclinical phase on IFNg and IL10 production by lymph 
node T cells. Lymph nodes cells from MOG35-55 immunized mice treated or not with MT2 in the preclinical 
phase of EAE were collected at 14 dpi and labelled with anti CD3/anti IFNg/anti IL10 antibodies. Upper panel: 
representative dot plots showing percentage of IFN-g+ (left) and IL-10+ (right) positive cells gated on total 
CD3+ cells. Lower panel: average percent of CD3+/IFN-g+ (left) and CD3+/IL-10+ (right) cells resulting from 6 
mice per group analyzed in 2 different experiments (mean±SEM; Unpaired t-test). Green columns: vehicle 
treated mice; orange columns: MT2 treated mice. 
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MT2 vs 13,3%±4,3% in controls, mean±SEM of 6 animals analyzed in two 
different experiments). 
According with these findings, the percentage of IFN-γ positive T cells within 
the spinal cord in MT2 treated mice was also strongly reduced (Figure 22), 
dropping to 6,42±0,07% (mean±SEM of 2 different experiments, carried out 
pooling cells from 3 samples in each one) versus 14,87±4,36% observed in 
control mice. 
Regarding the production of IL-10, this cytokine resulted unchanged by MT2 
treatment both in lymph node and spinal cord T cells (Figure 21-22).  
Figure 22. Effect of MT2 treatment during the EAE preclinical phase on phenotype of CNS infiltrating 
T cells. Lymphomonocytes isolated at 14 dpi from spinal cord of MOG35-55 immunized mice treated or 
not with MT2 in the preclinical phase of EAE were labelled with anti CD3/anti IFN-g/anti IL10 
antibodies and analyzed by flowcytometry. Upper panel: representative dot plots showing percentage of 
IFN-g+ (left) and IL-10+ (right) positive cells gated on total CD3+ cells. Lower panel: average percent 
of CD3+/IFN-g+ (left) and CD3+/IL-10+ (right) positive cells resulting from 2 independent experiments, 
pooling 3 animals per group in each experiment (mean±SEM). Green columns: vehicle treated mice; 
orange columns: MT2 treated mice. 
  
70 
 
In vitro effect of MT2 on MOG 35-55 specific T cell 
proliferation and cytokine production 
 
To better understand the effect of MT2 on T cells, we tested the effect of the drug 
in vitro on MOG 35-55 specific T cells (TCL), evaluating antigen driven 
proliferation and cytokine production. To this end TCL were stimulated with 
MOG 35-55 peptide in the presence or absence of MT2. We found that MT2 didn’t 
modify the proliferative response of TCL to MOG 35-55 peptide (Figure 23).  
Then, we investigated the inflammatory state of MT2 treated culture and controls 
by measuring level of IFN-γ, TNF-α, IL4, IL10, IL6 in TCL supernatant by 
Luminex assay. As for proliferative response, MT2 didn’t change cytokine 
profile of MOG35-55 stimulated cells (Figure 24). 
 
Figure 23. In vitro effect of MT2 on antigen specific T-cell proliferation. MOG 35-55 specific T cells. were 
stimulated with antigen in the presence or absence of MT2, added in culture medium. Proliferation was 
assessed by 3H-Thymidine incorporation. Left: Δcpm (mean cpm of antigen stimulated cells-mean cpm of not 
stimulated cells). Right: stimulation index (SI=mean cpm of antigen stimulated cells/mean cpm of not 
stimulated cells). Mean values±SEM of two independent experiments. 
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Effect of MT2 treatment on Cuprizone induced 
demyelination  
 
To verify a potential role of MT2 in protecting CNS during demyelination and 
inducing remyelinating processes, we tested our drug on a toxic non-autoimmune 
demyelination model, induced by feeding C57BL/6 mice with the copper 
chelator cuprizone.  
We fed animals for 35 days (0 – 35 experimental days, e.d.) and treated animals 
with MT2 or vehicle from day 21 to day 45 e.d.. Animals were sacrificed at days 
Figure 24. In vitro effect of MT2 on cytokine production by MOG35-55 TCL. IFN-g (A), TNF-α(B), IL-4 (C), IL-
10 (D) and IL-6 (E) were measured on TCL supernatant under basal condition (Background) and upon 48 hours 
stimulation with MOG35-55 (MOG), in the presence or absence of MT2 added in culture Mean pg/mL±SEM of 3 
independent experiments. 
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49 (7th week, during demyelinating phase) and 56 (8th week, during 
remyelinating phase). 
Microscopic analysis of myelin content  
We obtained sagittal sections from cerebellum and corpus callosum (CC), as 
shown in Figure 25. These slices were stained with GFAP and MBP antibodies 
in two different timing, using slices from demyelination phase (day 49) and 
remyelinating phase (day 56). In first phase slices, we noticed how myelin loss 
was more evident in MT2 tissue (arrow) compared to vehicle one (control). 
Figure 25. Effect of MT2 treatment on myelin loss in Cuprizone demyelinating model. We investigated the 
myelin loss in Cuprizone model in two different phases: the demyelinating phase, typical at 49th 
experimental day and the remyelinating one, usually visible after 56 days of experiment. First column is 
referred to the optical region at 49th experimental day, second column to the medial corpus callosum after 
56 experimental days. Pictures were taken at immunofluorescence microscope (20x magnification). First 
line is for vehicle samples, second line is for MT2-treated animals. Green: GFAP; Red: MBP; Blue: DAPI. 
opt: optic region; mCC: medial corpus callosum. Scale bar 200 µm. 
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Furthermore, the figure shows how, during remyelinating phase, loss of MBP+ 
cells was less broad but still evident (arrow). GFAP staining was similar in both 
tissues. 
Further investigation using transmission electron microscope (TEM) techniques 
(Figure 26) highlighted how myelin sheets were more plentiful in control 
sections of corpus callosum compared to MT2 ones.  
 
Electron microscope and fluorescence data were further confirmed by Luxol Fast 
Blue staining on corpus callosum sections, as shown in Figure 27. 
Figure 26. Transmission electron microscope micrographs of corpus callosum of cuprizone fed mice treated or 
not with MT2. Scale bar 1 µm. Electron micrograph magnification: x5000, x20000. Red square: particular of 
myelin sheets. 
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Effect of MT2 treatment on serum inflammatory markers 
Together with the evaluation of myelin content, we investigated the 
inflammatory state of MT2 treated animals and controls by measuring serum 
level of IFN-γ, IL10, IL17, IL6, TNF-α, CXCL1, CXCL2 and IL4 in at 49 and 
56 experimental days. We didn’t find any significant differences between two 
groups (Figure 28).  
 
Figure 27. Luxol fast blue staining of hippocampal fimbria and corpus callosum of cuprizone 
fed mice after treatment with MT2. Blue: myelin Scale bar 100 µm; abbreviations: fi: 
hippocampal fimbria; mCC: medial corpus callosum. 
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Figure 28. Cytokine and chemokine content in serum of Cuprizone fed mice under treatment with MT2.  A panel 
of cytokines and chemokines were measured by Luminex assay on serum samples collected at day 49 
(demyelinating phase) and day 56 (remyelinating phase). Green: vehicle treated mice; orange: MT2 treated mice. 
Mean±SEM of 6 mice per group. 
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Discussion 
 
Neurotrophins, such as NGF and BDNF, are a family of proteins that rules 
neuronal survival, synaptic function and neurotransmitter release. 
Furthermore, they can elicit the plasticity and growth of axons within the 
adult central and peripheral nervous system, as reviewed by Keefe et al. 
2017. In particular, their trophic feature leads to think of them as good 
molecules for therapeutic treatments, mostly for counteract inflammation 
induced tissue damage in pathologies on CNS. Despite this, their protein 
nature makes them unfavourable in a pharmacokinetic point of view, 
especially for central nervous system disorders, which involve the 
resistance to peptidase enzymes, the crossing of the BBB and poor 
diffusion in tissues. With these premises, we tested MT2, a patented non-
peptidic NGF and BDNF mimetic that potentially had the same 
neuroprotective beneficial without pharmacological adverse feature of a 
neurotrophins, but with a better bioavailability and metabolic stability. 
We tested MT2 in a rodent model of MS, the EAE MOG 35-55-induced, to 
understand if the drug could be a tool to treat animals during acute and 
chronic phases of the disease. 
In order to evaluate MT2 possible beneficial effect during the acute phase 
of EAE, the molecule was administered via i.p. from day 14th to day 22th. 
Results showed that the molecule significantly improved the clinical sign 
of the disease in MT2 treated animals comparing them to vehicle-treated 
group. Histopathological data were coherent with the improvement related 
to the clinical course of the disease. In particular, histopathological 
images, related to the animals observed during the acute phase of the 
disease, showed that in the spinal cord, considered the main representative 
site of EAE model, the number of lymphocytes and macrophages 
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infiltrates, principal responsible of neuronal damage, were reduced in 
MT2-treated animals compared controls ones. Meantime, the number of 
demyelinated areas was significantly lower in treated mice compared 
controls ones. In line with the drug ability (Scarpi et al 2012) in triggering 
early expression of MKP-1 and, then, leading to the phospho-p38 pathway 
activation, MT2 showed anti-inflammatory function: we observed a higher 
axonal integrity in the SC of treated mice compared to controls.  This result 
is coherent with the work by Villoslada and colleagues (Villoslada et al. 
2000), that showed that intracerebroventricular cannula administration of 
human NGF (hNGF) in common marmoset, improved the severe clinical 
sign of EAE. Our data lead us to think that MT2 acted as hNGF, improving 
clinical signs of EAE, and suppressing both the inflammatory and 
demyelinating components of CNS pathology. The effect mediated 
through MT2, that we observed in the acute phase of EAE, was similar to 
the one exerted by Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor, as 
explained in a recent work (Pifarre et al. 2014). Spanish researchers found 
that daily i.v. treatment with Sildenafil during peak of disease, rapidly 
ameliorated clinical symptoms and neuropathology that was related to 
BDNF up-regulation in immune and neuronal cells, suggesting its 
implication in the beneficial effects of the drug.  
Positive MT2 effect, observed on EAE clinical course and SC 
histopathology during acute phase, led us to think that MT2 can modulate 
both neuronal cell function and immune cell activity. The effects on 
neurons were evidenced in the in vitro model of organotypic spinal cord 
cell culture (developed in laboratories of professor Laura Ballerini, 
SISSA-ISAS, Trieste Italy). In this work, we demonstrated (see 
manuscript attached) that MT2 is able to counteract the effect of pro-
inflammatory cytokines cocktail preventing the synaptic alteration 
described without affecting the inflammatory response due to non-
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neuronal cells present in the culture. The drug was also able to confirm its 
ability to increase MKP-1 expression through TrkA pathway. 
In order to understand if MT2 directly act on immune system, we 
investigated T cells function in EAE MT2 treated mice during the acute 
phase. We observed that MT2 didn’t alter T cells proliferation ability 
versus MOG antigen, indicating that peripheral T cell responses were not 
affected by i.p. administration of MT2. We analyzed cytokines produced 
by T cells that  influence the course of autoimmune disorders (Charlton 
and Lafferty 1995). Through Luminex technology data, we noticed a lower 
IFN-γ, pro-inflammatory cytokine, production by T cells isolated from 
lymph nodes and spinal cord in MT2-treated mice compared to vehicle 
one, indicating that the protective effect of MT2 was possibly in part 
mediated through modulation of the peripheral and central network of 
cytokines produced by inflammatory cells. Regarding IL-10, an anti-
inflammatory cytokine, we noted a comparable production in treated and 
vehicle mice. This result agreed, again, with the work of Villoslada (2000), 
confirming that MT2 may play a role in ameliorating the disease 
mimicking hNGF. The neurotrophin can modulate cytokine expression by 
inflammatory cells in EAE, underlying its pivotal attitude of acting as an 
autocrine and anti-inflammatory cytokine. In diseases like EAE and MS, 
the presentation of myelin antigens to T cells is dependent on the 
expression of class-II HLA molecules on astrocytes and 
macrophages/microglia, which is upregulated by IFN-γ (Fierz et al. 1985). 
Thus, a possible effector mechanism for the protective action of MT2 
could be exerted decreasing the HLA class-II expression within the CNS, 
either indirectly through its effects on IFN-γ production or by a direct 
effect on astrocytes (Neumann et al. 1998). As a matter of fact, further 
investigations are needed in this mouse model, to determine whether the 
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effects of MT2 on CNS cytokine production provide long-term benefit in 
a chronic experimental design.  
Literature data reported that neurotrophins bind the pan-neurotrophin 
receptor (p75NTR) and tropomyosin receptor kinase (Trk) receptors, in 
particular NGF binds with high affinity TrkA and BDNF with the high 
affinity TrkB (Keefe et al. 2017). As widely demonstrated by molecular 
modeling studying by Scarpi et collegues, MT2 is a TrkA domain-5 
activator (TrkA-d5), NGF pathway mediator. Such domain shares a high 
sequence homology with the secondary structure of binding domain of 
TrkB, useful for the binding with BDNF (Wiesmann et al. 1999 and Ultsch 
et al. 1999). Furthermore, pharmacokinetic and binding studies made in 
prof. Cozzolino laboratory demonstrated the efficacy of peptidomimetic in 
activating a TrkB-mediated reaction (unpublished observations).  Several 
works reported that TrkA and TrkB receptors were expressed by neuronal 
and immune system as reviewed by Minnone G. and Keefe KM in two 
recent works. In order to understand the cellular targets of MT2 we 
investigated MT2 signaling pathway on T cells and spinal cord of EAE 
mice during the acute phase. We showed that MT2 triggered that pathway, 
increasing MKP-1 expression, phospho-p38 direct phosphatase. This latter 
protein is a member of MAP-Kinase family, that is deactivated through 
dephosphorylation, resulting not able to trigger the apoptotic pathway, as 
shown by the higher pro-caspase 3 presence in treated group than the 
vehicle one. This pathway, then, seems to be activated by the drug 
ameliorating the clinical picture, but further analysis was needed to 
understand if that happened in an exclusive way. 
We administered MT2 during chronic phase of EAE, aiming to understand 
if there was any therapeutic effect after the first inflammatory insult. 
Clinical observations consistent with histopathological investigations did 
not showed any amelioration, despite the recovery on the body weight. 
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This discrepancy between MT2 treatment during acute and chronic phase 
could be due to variable TrkA and TrkB expression level on immune cells 
or CNS cells or both. Actually, Oderfeld et al. showed that in rat during 
EAE TrkA and p75NTR expression in CNS, neuron and glia, was 
drastically reduced after acute phase (Oderfeld-Nowak et al. 2003). 
Therefore, a lower expression of TrkA and TrkB may affect the protective 
synergistic mechanism that is physiologically activated near MS lesions 
during the early stage of the disease (Song, 2013). The positive effects of 
MT2 treatment on Rotarod test may be due to a specific benefic action on 
cerebellum, not evidenced in our histopathological analysis, restricted to 
spinal cord. The same discussion may be extended to immune system cells, 
la Sala and colleagues (2000) demonstrated that, during in vitro monocyte 
differentiation into dendritic cell, TrkA expression was progressively lost 
(la Sala et al. 2000). This interpretation is further supported by our results 
during toxic demyelination, where MT2 induced tissue damage with an 
evident increase of demyelinated areas in comparison to vehicle group. In 
the same model, Cinthia Farina and colleagues (data presented at ISNI 
Congress 2013) showed that TrkB expression alone was strongly increased 
and its activation worsens astrocyte mediated damage. On the other hand, 
Bonetto and collegues showed that only selective binding of TrkA may 
determine protection against toxic demyelination (Bonetto et al. 2017). 
Taken together, our data suggest that MT2 is a anti-inflammatory and 
neuroprotective drug: its effect in acute phase of EAE is probably due to 
protection from pro-inflammatory cytokines expression by triggering the 
classical TrkA pathway. Our results on chronic EAE and Cuprizone led us 
to think that the double specificity for TrkA and TrkB could turn out to be 
a double-faced feature, activating pathways that were not intentionally 
targeted, causing damage in absence of ongoing inflammation events. 
Bibliography 
 
Abbas, N., A. Ahmad and A. R. Shakoori (2007). "Overexpression and purification of 
PreS region of hepatitis B virus antigenic surface protein adr subtype in Escherichia 
coli." J Biochem Mol Biol 40(6): 1002-1008. 
Ahlgren, C., A. Oden and J. Lycke (2012). "A nationwide survey of the prevalence of 
multiple sclerosis in immigrant populations of Sweden." Mult Scler 18(8): 1099-1107. 
Ashkenazi, A. and V. M. Dixit (1998). "Death receptors: signaling and modulation." 
Science 281(5381): 1305-1308. 
Ballerini, C., F. R. Guerini, G. Rombola, E. Rosati, L. Massacesi, P. Ferrante, D. Caputo, 
L. F. Talamanca, P. Naldi, M. Liguori, M. Alizadeh, P. Momigliano-Richiardi and S. 
D'Alfonso (2004). "HLA-multiple sclerosis association in continental Italy and 
correlation with disease prevalence in Europe." J Neuroimmunol 150(1-2): 178-185. 
Baranzini, S. E. and J. R. Oksenberg (2017). "The Genetics of Multiple Sclerosis: From 0 
to 200 in 50 Years." Trends Genet 33(12): 960-970. 
Barde, Y. A., D. Edgar and H. Thoenen (1982). "Purification of a new neurotrophic factor 
from mammalian brain." EMBO J 1(5): 549-553. 
Barten, L. J., D. R. Allington, K. A. Procacci and M. P. Rivey (2010). "New approaches in 
the management of multiple sclerosis." Drug Des Devel Ther 4: 343-366. 
Batoulis, H., M. S. Recks, K. Addicks and S. Kuerten (2011). "Experimental autoimmune 
encephalomyelitis--achievements and prospective advances." APMIS 119(12): 819-
830. 
Baxter, A. G. (2007). "The origin and application of experimental autoimmune 
encephalomyelitis." Nat Rev Immunol 7(11): 904-912. 
Berger, T., S. Weerth, K. Kojima, C. Linington, H. Wekerle and H. Lassmann (1997). 
"Experimental autoimmune encephalomyelitis: the antigen specificity of T 
lymphocytes determines the topography of lesions in the central and peripheral 
nervous system." Lab Invest 76(3): 355-364. 
Berkemeier, L. R., J. W. Winslow, D. R. Kaplan, K. Nikolics, D. V. Goeddel and A. 
Rosenthal (1991). "Neurotrophin-5: a novel neurotrophic factor that activates trk and 
trkB." Neuron 7(5): 857-866. 
Boatright, K. M. and G. S. Salvesen (2003). "Mechanisms of caspase activation." Curr 
Opin Cell Biol 15(6): 725-731. 
Bonetto, G., I. Charalampopoulos, A. Gravanis and D. Karagogeos (2017). "The novel 
synthetic microneurotrophin BNN27 protects mature oligodendrocytes against 
cuprizone-induced death, through the NGF receptor TrkA." Glia 65(8): 1376-1394. 
Bonini, S., A. Lambiase, S. Bonini, F. Angelucci, L. Magrini, L. Manni and L. Aloe (1996). 
"Circulating nerve growth factor levels are increased in humans with allergic diseases 
and asthma." Proc Natl Acad Sci U S A 93(20): 10955-10960. 
Boutros, T., E. Chevet and P. Metrakos (2008). "Mitogen-activated protein (MAP) 
kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer." 
Pharmacol Rev 60(3): 261-310. 
Brinkmann, V. (2009). "FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects 
in the immune and the central nervous system." Br J Pharmacol 158(5): 1173-1182. 
  
83 
 
Brodie, C. and E. W. Gelfand (1992). "Functional nerve growth factor receptors on 
human B lymphocytes. Interaction with IL-2." J Immunol 148(11): 3492-3497. 
Bruni, A., E. Bigon, E. Boarato, L. Mietto, A. Leon and G. Toffano (1982). "Interaction 
between nerve growth factor and lysophosphatidylserine on rat peritoneal mast cells." 
FEBS Lett 138(2): 190-192. 
Buck, D. and B. Hemmer (2011). "Treatment of multiple sclerosis: current concepts and 
future perspectives." Journal of Neurology 258(10): 1747-1762. 
Bullo, M., M. R. Peeraully and P. Trayhurn (2005). "Stimulation of NGF expression and 
secretion in 3T3-L1 adipocytes by prostaglandins PGD2, PGJ2, and Delta12-PGJ2." Am 
J Physiol Endocrinol Metab 289(1): E62-67. 
Caporali, A. and C. Emanueli (2009). "Cardiovascular actions of neurotrophins." Physiol 
Rev 89(1): 279-308. 
Charlton, B. and K. J. Lafferty (1995). "The Th1/Th2 balance in autoimmunity." Curr 
Opin Immunol 7(6): 793-798. 
Chinnaiyan, A. M. (1999). "The apoptosome: heart and soul of the cell death machine." 
Neoplasia 1(1): 5-15. 
Clifford, D. B., A. De Luca, D. M. Simpson, G. Arendt, G. Giovannoni and A. Nath (2010). 
"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with 
multiple sclerosis: lessons from 28 cases." Lancet Neurol 9(4): 438-446. 
Cocco, E., R. Murru, G. Costa, A. Kumar, E. Pieroni, C. Melis, L. Barberini, C. Sardu, L. 
Lorefice, G. Fenu, J. Frau, G. Coghe, N. Carboni and M. G. Marrosu (2013). "Interaction 
between HLA-DRB1-DQB1 haplotypes in Sardinian multiple sclerosis population." PLoS 
One 8(4): e59790. 
Cohen, S. (1960). "Purification of a Nerve-Growth Promoting Protein from the Mouse 
Salivary Gland and Its Neuro-Cytotoxic Antiserum." Proc Natl Acad Sci U S A 46(3): 302-
311. 
Comi, G., M. Radaelli and P. Soelberg Sorensen (2017). "Evolving concepts in the 
treatment of relapsing multiple sclerosis." Lancet 389(10076): 1347-1356. 
Compston, A. (1988). "The 150th anniversary of the first depiction of the lesions of 
multiple sclerosis." J Neurol Neurosurg Psychiatry 51(10): 1249-1252. 
Compston, A. (2006). "The basis for treatment in multiple sclerosis." Acta Neurol Scand 
Suppl 183: 41-47. 
Cory, S. and J. M. Adams (2002). "The Bcl2 family: regulators of the cellular life-or-
death switch." Nat Rev Cancer 2(9): 647-656. 
Dendrou, C. A., L. Fugger and M. A. Friese (2015). "Immunopathology of multiple 
sclerosis." Nat Rev Immunol 15(9): 545-558. 
Denic, A., A. J. Johnson, A. J. Bieber, A. E. Warrington, M. Rodriguez and I. Pirko (2011). 
"The relevance of animal models in multiple sclerosis research." Pathophysiology 
18(1): 21-29. 
Ehrhard, P. B., P. Erb, U. Graumann and U. Otten (1993). "Expression of nerve growth 
factor and nerve growth factor receptor tyrosine kinase Trk in activated CD4-positive 
T-cell clones." Proc Natl Acad Sci U S A 90(23): 10984-10988. 
Ellis, P. A., I. E. Smith and M. Dowsett (1996). "Apoptosis--its role in tumour growth 
and therapy." Cytopathology 7(3): 201-203. 
Elmore, S. (2007). "Apoptosis: a review of programmed cell death." Toxicol Pathol 
35(4): 495-516. 
  
84 
 
Eylar, E. H., J. Caccam, J. J. Jackson, F. C. Westall and A. B. Robinson (1970). 
"Experimental allergic encephalomyelitis: synthesis of disease-inducing site of the 
basic protein." Science 168(3936): 1220-1223. 
Fierz, W., B. Endler, K. Reske, H. Wekerle and A. Fontana (1985). "Astrocytes as 
antigen-presenting cells. I. Induction of Ia antigen expression on astrocytes by T cells 
via immune interferon and its effect on antigen presentation." J Immunol 134(6): 3785-
3793. 
Fletcher, J. M., S. J. Lalor, C. M. Sweeney, N. Tubridy and K. H. Mills (2010). "T cells in 
multiple sclerosis and experimental autoimmune encephalomyelitis." Clin Exp 
Immunol 162(1): 1-11. 
Franciotta, D., M. Salvetti, F. Lolli, B. Serafini and F. Aloisi (2008). "B cells and multiple 
sclerosis." Lancet Neurol 7(9): 852-858. 
Franklin, C. C. and A. S. Kraft (1997). "Conditional expression of the mitogen-activated 
protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and 
stress-activated protein kinase in U937 cells." J Biol Chem 272(27): 16917-16923. 
Freund, J., E. R. Stern and T. M. Pisani (1947). "Isoallergic encephalomyelitis and 
radiculitis in guinea pigs after one injection of brain and Mycobacteria in water-in-oil 
emulsion." J Immunol 57(2): 179-194. 
Ghatan, S., S. Larner, Y. Kinoshita, M. Hetman, L. Patel, Z. Xia, R. J. Youle and R. S. 
Morrison (2000). "p38 MAP kinase mediates bax translocation in nitric oxide-induced 
apoptosis in neurons." J Cell Biol 150(2): 335-347. 
Giuliani, F., L. M. Metz, T. Wilson, Y. Fan, A. Bar-Or and V. W. Yong (2005). "Additive 
effect of the combination of glatiramer acetate and minocycline in a model of MS." J 
Neuroimmunol 158(1-2): 213-221. 
Gold, R., F. Buttgereit and K. V. Toyka (2001). "Mechanism of action of 
glucocorticosteroid hormones: possible implications for therapy of 
neuroimmunological disorders." J Neuroimmunol 117(1-2): 1-8. 
Gotz, R., R. Koster, C. Winkler, F. Raulf, F. Lottspeich, M. Schartl and H. Thoenen (1994). 
"Neurotrophin-6 is a new member of the nerve growth factor family." Nature 
372(6503): 266-269. 
Goverman, J., A. Woods, L. Larson, L. P. Weiner, L. Hood and D. M. Zaller (1993). 
"Transgenic mice that express a myelin basic protein-specific T cell receptor develop 
spontaneous autoimmunity." Cell 72(4): 551-560. 
Green, D. R. and J. C. Reed (1998). "Mitochondria and apoptosis." Science 281(5381): 
1309-1312. 
Gudat, F., A. Laubscher, U. Otten and A. Pletscher (1981). "Shape changes induced by 
biologically active peptides and nerve growth factor in blood platelets of rabbits." Br J 
Pharmacol 74(3): 533-538. 
Gudi, V., S. Gingele, T. Skripuletz and M. Stangel (2014). "Glial response during 
cuprizone-induced de- and remyelination in the CNS: lessons learned." Front Cell 
Neurosci 8: 73. 
Hafler, D. A., J. M. Slavik, D. E. Anderson, K. C. O'Connor, P. De Jager and C. Baecher-
Allan (2005). "Multiple sclerosis." Immunological Reviews 204(1): 208-231. 
Hansen, T., A. Skytthe, E. Stenager, H. C. Petersen, H. Brønnum-Hansen and K. O. Kyvik 
(2005). "Concordance for multiple sclerosis in Danish twins: an update of a nationwide 
study." Multiple Sclerosis Journal 11(5): 504-510. 
  
85 
 
Hartung, H. P., B. C. Kieseier and B. Hemmer (2005). "Purely systemically active anti-
inflammatory treatments are adequate to control multiple sclerosis." J Neurol 252 
Suppl 5: v30-37. 
Hauser, S. L., D. M. Dawson, J. R. Lehrich, M. F. Beal, S. V. Kevy, R. D. Propper, J. A. Mills 
and H. L. Weiner (1983). "Intensive immunosuppression in progressive multiple 
sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, 
plasma exchange, and ACTH." N Engl J Med 308(4): 173-180. 
Hofstetter, H. H., C. L. Shive and T. G. Forsthuber (2002). "Pertussis Toxin Modulates 
the Immune Response to Neuroantigens Injected in Incomplete Freund’s Adjuvant: 
Induction of Th1 Cells and Experimental Autoimmune Encephalomyelitis in the 
Presence of High Frequencies of Th2 Cells." The Journal of Immunology 169(1): 117-
125. 
Hohn, A., J. Leibrock, K. Bailey and Y. A. Barde (1990). "Identification and 
characterization of a novel member of the nerve growth factor/brain-derived 
neurotrophic factor family." Nature 344(6264): 339-341. 
Hoppenbrouwers, I. A. and R. Q. Hintzen (2011). "Genetics of multiple sclerosis." 
Biochim Biophys Acta 1812(2): 194-201. 
Ichim, G., S. Tauszig-Delamasure and P. Mehlen (2012). "Neurotrophins and cell 
death." Exp Cell Res 318(11): 1221-1228. 
Isobe, N., A. Keshavan, P. Gourraud and et al. (2016). "Association of hla genetic risk 
burden with disease phenotypes in multiple sclerosis." JAMA Neurology 73(7): 795-
802. 
Israels, L. G. and E. D. Israels (1999). "Apoptosis." Stem Cells 17(5): 306-313. 
Jezek, D. and V. Kozina (2009). "[Apoptosis during embryo development]." Acta Med 
Croatica 63 Suppl 2: 37-41. 
Keefe, K. M., I. S. Sheikh and G. M. Smith (2017). "Targeting Neurotrophins to Specific 
Populations of Neurons: NGF, BDNF, and NT-3 and Their Relevance for Treatment of 
Spinal Cord Injury." Int J Mol Sci 18(3). 
Kerr, J. F. (2002). "History of the events leading to the formulation of the apoptosis 
concept." Toxicology 181-182: 471-474. 
Kerschensteiner, M., E. Gallmeier, L. Behrens, V. V. Leal, T. Misgeld, W. E. Klinkert, R. 
Kolbeck, E. Hoppe, R. L. Oropeza-Wekerle, I. Bartke, C. Stadelmann, H. Lassmann, H. 
Wekerle and R. Hohlfeld (1999). "Activated human T cells, B cells, and monocytes 
produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: 
a neuroprotective role of inflammation?" J Exp Med 189(5): 865-870. 
Kerschensteiner, M., C. Stadelmann, G. Dechant, H. Wekerle and R. Hohlfeld (2003). 
"Neurotrophic cross-talk between the nervous and immune systems: implications for 
neurological diseases." Ann Neurol 53(3): 292-304. 
Khorooshi, R., N. Asgari, M. T. Morch, C. T. Berg and T. Owens (2015). "Hypersensitivity 
Responses in the Central Nervous System." Front Immunol 6: 517. 
Kieseier, B. C. and H. P. Hartung (2003). "Current disease-modifying therapies in 
multiple sclerosis." Semin Neurol 23(2): 133-146. 
Kimata, H., A. Yoshida, C. Ishioka, T. Kusunoki, S. Hosoi and H. Mikawa (1991). "Nerve 
growth factor specifically induces human IgG4 production." Eur J Immunol 21(1): 137-
141. 
Koh, D. R., W. P. Fung-Leung, A. Ho, D. Gray, H. Acha-Orbea and T. W. Mak (1992). 
"Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- 
mice." Science 256(5060): 1210-1213. 
  
86 
 
Korn, T. (2008). "Pathophysiology of multiple sclerosis." J Neurol 255 Suppl 6: 2-6. 
Krysko, D. V., T. Vanden Berghe, K. D'Herde and P. Vandenabeele (2008). "Apoptosis 
and necrosis: detection, discrimination and phagocytosis." Methods 44(3): 205-221. 
Kuerten, S., A. Rottlaender, M. Rodi, V. B. Velasco, Jr., M. Schroeter, C. Kaiser, K. 
Addicks, M. Tary-Lehmann and P. V. Lehmann (2010). "The clinical course of EAE is 
reflected by the dynamics of the neuroantigen-specific T cell compartment in the 
blood." Clin Immunol 137(3): 422-432. 
Kuusisto, H., J. Kaprio, E. Kinnunen, T. Luukkaala, M. Koskenvuo and I. Elovaara (2008). 
"Concordance and heritability of multiple sclerosis in Finland: study on a nationwide 
series of twins." European Journal of Neurology 15(10): 1106-1110. 
Kwak, S. P., D. J. Hakes, K. J. Martell and J. E. Dixon (1994). "Isolation and 
characterization of a human dual specificity protein-tyrosine phosphatase gene." J Biol 
Chem 269(5): 3596-3604. 
la Sala, A., S. Corinti, M. Federici, H. U. Saragovi and G. Girolomoni (2000). "Ligand 
activation of nerve growth factor receptor TrkA protects monocytes from apoptosis." 
J Leukoc Biol 68(1): 104-110. 
Langer-Gould , A., S. W. Atlas , A. J. Green , A. W. Bollen  and D. Pelletier (2005). 
"Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab." 
New England Journal of Medicine 353(4): 375-381. 
Lassmann, H. and R. M. Ransohoff (2004). "The CD4-Th1 model for multiple sclerosis: 
a critical [correction of crucial] re-appraisal." Trends Immunol 25(3): 132-137. 
Lebar, R. and C. Vincent (1981). "Tentative identification of a second central nervous 
system myelin membrane autoantigen (M2) by a biochemical comparison with the 
basic protein (BP)." J Neuroimmunol 1(4): 367-389. 
LeSauteur, L., L. Wei, B. F. Gibbs and H. U. Saragovi (1995). "Small peptide mimics of 
nerve growth factor bind TrkA receptors and affect biological responses." J Biol Chem 
270(12): 6564-6569. 
Levi-Montalcini, R. and B. Booker (1960). "Destruction of the Sympathetic Ganglia in 
Mammals by an Antiserum to a Nerve-Growth Protein." Proc Natl Acad Sci U S A 46(3): 
384-391. 
Levi-Montalcini, R. and V. Hamburger (1951). "Selective growth stimulating effects of 
mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo." 
J Exp Zool 116(2): 321-361. 
Linker, R. A. and R. Gold (2013). "Dimethyl fumarate for treatment of multiple sclerosis: 
mechanism of action, effectiveness, and side effects." Curr Neurol Neurosci Rep 
13(11): 394. 
Lipnik-Stangelj, M. and M. Carman-Krzan (2004). "Activation of histamine H1-receptor 
enhances neurotrophic factor secretion from cultured astrocytes." Inflamm Res 53(6): 
245-252. 
Lublin, F. D. (2014). "New Multiple Sclerosis Phenotypic Classification." European 
Neurology 72(suppl 1)(Suppl. 1): 1-5. 
Luckey, D., D. Bastakoty and A. K. Mangalam (2011). "Role of HLA class II genes in 
susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice." 
J Autoimmun 37(2): 122-128. 
Mandal, C., A. Dutta, A. Mallick, S. Chandra, L. Misra, R. S. Sangwan and C. Mandal 
(2008). "Withaferin A induces apoptosis by activating p38 mitogen-activated protein 
kinase signaling cascade in leukemic cells of lymphoid and myeloid origin through 
mitochondrial death cascade." Apoptosis 13(12): 1450-1464. 
  
87 
 
Manning, P. T., J. H. Russell, B. Simmons and E. M. Johnson, Jr. (1985). "Protection from 
guanethidine-induced neuronal destruction by nerve growth factor: effect of NGF on 
immune function." Brain Res 340(1): 61-69. 
Manouchehrinia, A. and C. S. Constantinescu (2012). "Cost-effectiveness of disease-
modifying therapies in multiple sclerosis." Curr Neurol Neurosci Rep 12(5): 592-600. 
Martenson, R. E., G. E. Deibler and M. W. Kies (1969). "Microheterogeneity of guinea 
pig myelin basic protein." J Biol Chem 244(16): 4261-4267. 
Matsuda, H., M. D. Coughlin, J. Bienenstock and J. A. Denburg (1988). "Nerve growth 
factor promotes human hemopoietic colony growth and differentiation." Proc Natl 
Acad Sci U S A 85(17): 6508-6512. 
Matsuda, N., N. Morita, K. Matsuda and M. Watanabe (1998). "Proliferation and 
differentiation of human osteoblastic cells associated with differential activation of 
MAP kinases in response to epidermal growth factor, hypoxia, and mechanical stress 
in vitro." Biochem Biophys Res Commun 249(2): 350-354. 
McTigue, D. M., P. J. Horner, B. T. Stokes and F. H. Gage (1998). "Neurotrophin-3 and 
brain-derived neurotrophic factor induce oligodendrocyte proliferation and 
myelination of regenerating axons in the contused adult rat spinal cord." J Neurosci 
18(14): 5354-5365. 
Meeker, R. B. and K. S. Williams (2015). "The p75 neurotrophin receptor: at the 
crossroad of neural repair and death." Neural Regen Res 10(5): 721-725. 
Metzstein, M. M., G. M. Stanfield and H. R. Horvitz (1998). "Genetics of programmed 
cell death in C. elegans: past, present and future." Trends Genet 14(10): 410-416. 
Minnone, G., F. De Benedetti and L. Bracci-Laudiero (2017). "NGF and Its Receptors in 
the Regulation of Inflammatory Response." Int J Mol Sci 18(5). 
Mumford, C. J., N. W. Wood, H. Kellar-Wood, J. W. Thorpe, D. H. Miller and D. A. 
Compston (1994). "The British Isles survey of multiple sclerosis in twins." Neurology 
44(1): 11-15. 
Nathanson, N. and A. Miller (1978). "Epidemiology of multiple sclerosis: critique of the 
evidence for a viral etiology." Am J Epidemiol 107(6): 451-461. 
Neuhaus, O., C. Farina, H. Wekerle and R. Hohlfeld (2001). "Mechanisms of action of 
glatiramer acetate in multiple sclerosis." Neurology 56(6): 702-708. 
Neumann, H., T. Misgeld, K. Matsumuro and H. Wekerle (1998). "Neurotrophins inhibit 
major histocompatibility class II inducibility of microglia: involvement of the p75 
neurotrophin receptor." Proc Natl Acad Sci U S A 95(10): 5779-5784. 
Noseworthy, J. H., C. Lucchinetti, M. Rodriguez and B. G. Weinshenker (2000). 
"Multiple sclerosis." N Engl J Med 343(13): 938-952. 
Oderfeld-Nowak, B., M. Zaremba, A. W. Lipkowski, B. Kwiatkowska-Patzer, V. Triaca 
and L. Aloe (2003). "High-affinity NGF receptor in the rat spinal cord during acute and 
chronic phases of experimental autoimmune encephalomyelitis: a possible functional 
significance." Arch Ital Biol 141(2-3): 103-116. 
Olerup, O. and J. Hillert (1991). "HLA class II-associated genetic susceptibility in 
multiple sclerosis: a critical evaluation." Tissue Antigens 38(1): 1-15. 
Olsson, T., I. Dahlman, E. Wallstrom, R. Weissert and F. Piehl (2000). "Genetics of rat 
neuroinflammation." J Neuroimmunol 107(2): 191-200. 
Orrenius, S., B. Zhivotovsky and P. Nicotera (2003). "Regulation of cell death: the 
calcium-apoptosis link." Nat Rev Mol Cell Biol 4(7): 552-565. 
Otten, U., J. B. Baumann and J. Girard (1984). "Nerve growth factor induces plasma 
extravasation in rat skin." Eur J Pharmacol 106(1): 199-201. 
  
88 
 
Paterson, P. Y. (1960). "Transfer of allergic encephalomyelitis in rats by means of lymph 
node cells." J Exp Med 111: 119-136. 
Pelletier, D. and D. A. Hafler (2012). "Fingolimod for multiple sclerosis." N Engl J Med 
366(4): 339-347. 
Pifarre, P., M. Gutierrez-Mecinas, J. Prado, L. Usero, C. Roura-Mir, M. Giralt, J. Hidalgo 
and A. Garcia (2014). "Phosphodiesterase 5 inhibition at disease onset prevents 
experimental autoimmune encephalomyelitis progression through immunoregulatory 
and neuroprotective actions." Exp Neurol 251: 58-71. 
Poduslo, S. E. (1983). "Proteins and glycoproteins in plasma membranes and in the 
membrane lamellae produced by purified oligodendroglia in culture." Biochim Biophys 
Acta 728(1): 59-65. 
Polman, C. H., P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. 
T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, M. Toal, F. Lynn, M. A. Panzara, A. W. 
Sandrock and A. Investigators (2006). "A randomized, placebo-controlled trial of 
natalizumab for relapsing multiple sclerosis." N Engl J Med 354(9): 899-910. 
Popescu, B. F., I. Pirko and C. F. Lucchinetti (2013). "Pathology of multiple sclerosis: 
where do we stand?" Continuum (Minneap Minn) 19(4 Multiple Sclerosis): 901-921. 
Potelle, S., A. Klein and F. Foulquier (2015). "Golgi post-translational modifications and 
associated diseases." J Inherit Metab Dis 38(4): 741-751. 
Prencipe, G., G. Minnone, R. Strippoli, L. De Pasquale, S. Petrini, I. Caiello, L. Manni, F. 
De Benedetti and L. Bracci-Laudiero (2014). "Nerve growth factor downregulates 
inflammatory response in human monocytes through TrkA." J Immunol 192(7): 3345-
3354. 
Raingeaud, J., S. Gupta, J. S. Rogers, M. Dickens, J. Han, R. J. Ulevitch and R. J. Davis 
(1995). "Pro-inflammatory cytokines and environmental stress cause p38 mitogen-
activated protein kinase activation by dual phosphorylation on tyrosine and 
threonine." J Biol Chem 270(13): 7420-7426. 
Ransohoff, R. M., D. A. Hafler and C. F. Lucchinetti (2015). "Multiple sclerosis[mdash]a 
quiet revolution." Nat Rev Neurol 11(3): 134-142. 
Reichardt, L. F. (2006). "Neurotrophin-regulated signalling pathways." Philos Trans R 
Soc Lond B Biol Sci 361(1473): 1545-1564. 
Rivers, T. M., D. H. Sprunt and G. P. Berry (1933). "Observations on Attempts to 
Produce Acute Disseminated Encephalomyelitis in Monkeys." J Exp Med 58(1): 39-53. 
Rosini, P., G. De Chiara, M. Lucibello, E. Garaci, F. Cozzolino and M. Torcia (2000). "NGF 
withdrawal induces apoptosis in CESS B cell line through p38 MAPK activation and Bcl-
2 phosphorylation." Biochem Biophys Res Commun 278(3): 753-759. 
Ruckemann, K., L. D. Fairbanks, E. A. Carrey, C. M. Hawrylowicz, D. F. Richards, B. 
Kirschbaum and H. A. Simmonds (1998). "Leflunomide inhibits pyrimidine de novo 
synthesis in mitogen-stimulated T-lymphocytes from healthy humans." J Biol Chem 
273(34): 21682-21691. 
Ryser, S., A. Massiha, I. Piuz and W. Schlegel (2004). "Stimulated initiation of mitogen-
activated protein kinase phosphatase-1 (MKP-1) gene transcription involves the 
synergistic action of multiple cis-acting elements in the proximal promoter." Biochem 
J 378(Pt 2): 473-484. 
Ryser, S., S. Tortola, G. van Haasteren, M. Muda, S. Li and W. Schlegel (2001). "MAP 
kinase phosphatase-1 gene transcription in rat neuroendocrine cells is modulated by a 
calcium-sensitive block to elongation in the first exon." J Biol Chem 276(36): 33319-
33327. 
  
89 
 
Saadoun, S., P. Waters, B. A. Bell, A. Vincent, A. S. Verkman and M. C. Papadopoulos 
(2010). "Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human 
complement produces neuromyelitis optica lesions in mice." Brain 133(Pt 2): 349-361. 
Sadovnick, A. D. (1993). "Familial recurrence risks and inheritance of multiple 
sclerosis." Curr Opin Neurol Neurosurg 6(2): 189-194. 
Saelens, X., N. Festjens, L. Vande Walle, M. van Gurp, G. van Loo and P. Vandenabeele 
(2004). "Toxic proteins released from mitochondria in cell death." Oncogene 23(16): 
2861-2874. 
Saragovi, H. U., M. I. Greene, R. A. Chrusciel and M. Kahn (1992). "Loops and secondary 
structure mimetics: development and applications in basic science and rational drug 
design." Biotechnology (N Y) 10(7): 773-778. 
Scarpi, D., D. Cirelli, C. Matrone, G. Castronovo, P. Rosini, E. G. Occhiato, F. Romano, L. 
Bartali, A. M. Clemente, G. Bottegoni, A. Cavalli, G. De Chiara, P. Bonini, P. Calissano, 
A. T. Palamara, E. Garaci, M. G. Torcia, A. Guarna and F. Cozzolino (2012). "Low 
molecular weight, non-peptidic agonists of TrkA receptor with NGF-mimetic activity." 
Cell Death Dis 3: e389. 
Schmidt, S. (1999). "Candidate autoantigens in multiple sclerosis." Mult Scler 5(3): 147-
160. 
Scimeca, J. C., M. J. Servant, J. O. Dyer and S. Meloche (1997). "Essential role of calcium 
in the regulation of MAP kinase phosphatase-1 expression." Oncogene 15(6): 717-725. 
Seamons, A., A. Perchellet and J. Goverman (2003). "Immune tolerance to myelin 
proteins." Immunol Res 28(3): 201-221. 
Shipp, L. E., J. V. Lee, C. Y. Yu, M. Pufall, P. Zhang, D. K. Scott and J. C. Wang (2010). 
"Transcriptional regulation of human dual specificity protein phosphatase 1 (DUSP1) 
gene by glucocorticoids." PLoS One 5(10): e13754. 
Skaper, S. D. (2011). "Peptide mimetics of neurotrophins and their receptors." Curr 
Pharm Des 17(25): 2704-2718. 
Skokou, M., E. Soubasi and P. Gourzis (2012). "Depression in multiple sclerosis: a 
review of assessment and treatment approaches in adult and pediatric populations." 
ISRN Neurol 2012: 427102. 
Spain, R. I., M. H. Cameron and D. Bourdette (2009). "Recent developments in multiple 
sclerosis therapeutics." BMC Med 7: 74. 
Sriram, S. and I. Steiner (2005). "Experimental allergic encephalomyelitis: a misleading 
model of multiple sclerosis." Ann Neurol 58(6): 939-945. 
Stadelmann, C., M. Kerschensteiner, T. Misgeld, W. Bruck, R. Hohlfeld and H. Lassmann 
(2002). "BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective 
interactions between immune and neuronal cells?" Brain 125(Pt 1): 75-85. 
Stanzel, R. D., S. Lourenssen and M. G. Blennerhassett (2008). "Inflammation causes 
expression of NGF in epithelial cells of the rat colon." Exp Neurol 211(1): 203-213. 
Steinman, L. (1997). "Some misconceptions about understanding autoimmunity 
through experiments with knockouts." J Exp Med 185(12): 2039-2041. 
Stuke, K., P. Flachenecker, U. K. Zettl, W. G. Elias, M. Freidel, J. Haas, D. Pitschnau-
Michel, S. Schimrigk and P. Rieckmann (2009). "Symptomatology of MS: results from 
the German MS Registry." J Neurol 256(11): 1932-1935. 
Su, B. and M. Karin (1996). "Mitogen-activated protein kinase cascades and regulation 
of gene expression." Curr Opin Immunol 8(3): 402-411. 
  
90 
 
Thorpe, L. W. and J. R. Perez-Polo (1987). "The influence of nerve growth factor on the 
in vitro proliferative response of rat spleen lymphocytes." J Neurosci Res 18(1): 134-
139. 
Torcia, M., G. De Chiara, L. Nencioni, S. Ammendola, D. Labardi, M. Lucibello, P. Rosini, 
L. N. Marlier, P. Bonini, P. Dello Sbarba, A. T. Palamara, N. Zambrano, T. Russo, E. Garaci 
and F. Cozzolino (2001). "Nerve growth factor inhibits apoptosis in memory B 
lymphocytes via inactivation of p38 MAPK, prevention of Bcl-2 phosphorylation, and 
cytochrome c release." J Biol Chem 276(42): 39027-39036. 
Tremlett, H., Y. Zhao, V. Devonshire and U. B. C. Neurologists (2009). "Natural history 
comparisons of primary and secondary progressive multiple sclerosis reveals 
differences and similarities." J Neurol 256(3): 374-381. 
Ultsch, M. H., C. Wiesmann, L. C. Simmons, J. Henrich, M. Yang, D. Reilly, S. H. Bass and 
A. M. de Vos (1999). "Crystal structures of the neurotrophin-binding domain of TrkA, 
TrkB and TrkC." J Mol Biol 290(1): 149-159. 
Van Epps, H. L. (2005). "Thomas Rivers and the EAE model." The Journal of 
Experimental Medicine 202(1): 4-4. 
van Horssen, J., J. A. Drexhage, T. Flor, W. Gerritsen, P. van der Valk and H. E. de Vries 
(2010). "Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis 
lesions." Free Radic Biol Med 49(8): 1283-1289. 
Vega, J. A., O. Garcia-Suarez, J. Hannestad, M. Perez-Perez and A. Germana (2003). 
"Neurotrophins and the immune system." J Anat 203(1): 1-19. 
Villoslada, P. and C. P. Genain (2004). "Role of nerve growth factor and other trophic 
factors in brain inflammation." Prog Brain Res 146: 403-414. 
Villoslada, P., S. L. Hauser, I. Bartke, J. Unger, N. Heald, D. Rosenberg, S. W. Cheung, W. 
C. Mobley, S. Fisher and C. P. Genain (2000). "Human nerve growth factor protects 
common marmosets against autoimmune encephalomyelitis by switching the balance 
of T helper cell type 1 and 2 cytokines within the central nervous system." J Exp Med 
191(10): 1799-1806. 
von Boyen, G. B., M. Steinkamp, M. Reinshagen, K. H. Schafer, G. Adler and J. Kirsch 
(2006). "Nerve growth factor secretion in cultured enteric glia cells is modulated by 
proinflammatory cytokines." J Neuroendocrinol 18(11): 820-825. 
Wancket, L. M., W. J. Frazier and Y. Liu (2012). "Mitogen-activated protein kinase 
phosphatase (MKP)-1 in immunology, physiology, and disease." Life Sci 90(7-8): 237-
248. 
Wandinger, K., W. Jabs, A. Siekhaus, S. Bubel, P. Trillenberg, H. Wagner, K. Wessel, H. 
Kirchner and H. Hennig (2000). "Association between clinical disease activity and 
Epstein-Barr virus reactivation in MS." Neurology 55(2): 178-184. 
Wang, Z., N. Cao, D. Nantajit, M. Fan, Y. Liu and J. J. Li (2008). "Mitogen-activated 
protein kinase phosphatase-1 represses c-Jun NH2-terminal kinase-mediated 
apoptosis via NF-kappaB regulation." J Biol Chem 283(30): 21011-21023. 
Wekerle, H., K. Kojima, J. Lannes-Vieira, H. Lassmann and C. Linington (1994). "Animal 
models." Ann Neurol 36 Suppl: S47-53. 
Weston, C. R. and R. J. Davis (2007). "The JNK signal transduction pathway." Curr Opin 
Cell Biol 19(2): 142-149. 
Wiesmann, C., M. H. Ultsch, S. H. Bass and A. M. de Vos (1999). "Crystal structure of 
nerve growth factor in complex with the ligand-binding domain of the TrkA receptor." 
Nature 401(6749): 184-188. 
  
91 
 
Yednock, T. A., C. Cannon, L. C. Fritz, F. Sanchez-Madrid, L. Steinman and N. Karin 
(1992). "Prevention of experimental autoimmune encephalomyelitis by antibodies 
against alpha 4 beta 1 integrin." Nature 356(6364): 63-66. 
Yong, V. W., S. Chabot, O. Stuve and G. Williams (1998). "Interferon beta in the 
treatment of multiple sclerosis: mechanisms of action." Neurology 51(3): 682-689. 
Zaccaro, M. C., H. B. Lee, M. Pattarawarapan, Z. Xia, A. Caron, P. J. L'Heureux, Y. Bengio, 
K. Burgess and H. U. Saragovi (2005). "Selective small molecule peptidomimetic ligands 
of TrkC and TrkA receptors afford discrete or complete neurotrophic activities." Chem 
Biol 12(9): 1015-1028. 
Zhang, B., T. Yamamura, T. Kondo, M. Fujiwara and T. Tabira (1997). "Regulation of 
experimental autoimmune encephalomyelitis by natural killer (NK) cells." J Exp Med 
186(10): 1677-1687. 
Zhang, Y., D. Y. Leung, B. N. Richers, Y. Liu, L. K. Remigio, D. W. Riches and E. Goleva 
(2012). "Vitamin D inhibits monocyte/macrophage proinflammatory cytokine 
production by targeting MAPK phosphatase-1." J Immunol 188(5): 2127-2135. 
Zhou, S. R., M. A. Moscarello and J. N. Whitaker (1995). "The effects of citrullination or 
variable amino-terminus acylation on the encephalitogenicity of human myelin basic 
protein in the PL/J mouse." J Neuroimmunol 62(2): 147-152. 
Zujovic, V., C. Doucerain, A. Hidalgo, C. Bachelin, F. Lachapelle, R. Weissert, C. 
Stadelmann, C. Linington and A. Baron-Van Evercooren (2012). "Exogenous schwann 
cells migrate, remyelinate and promote clinical recovery in experimental auto-immune 
encephalomyelitis." PLoS One 7(9): e42667. 
Olerup O et al., (1991) HLA class II-associated genetic susceptibility in multiple 
sclerosis: a critical evaluation. Tissue Antigen 
 
Petersen T et al., (2012) Effects of interferon-beta therapy on elements in the 
antiviral immune response towards the human herpesviruses EBV, HSV, and 
VZV, and to the human endogenous retroviruses HERV-H and HERV-W in 
multiple sclerosis. Journal of Neuroimmunology 
 
P.S. Hench, E.C. Kendall, C.H. Slocumb, H.F. Polley (1949) The effect of a 
hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: 
compound E) and of pituitary adrenocortical hormone in arthritis: preliminary 
report Ann Rheum Dis 
 
Luckey D, Bastakoty D, Mangalam AK. (2011) Role of HLA class II genes in 
susceptibility and resistance to multiple sclerosis: studies using HLA transgenic 
mice. J Autoimmun.   
 
Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC 
(2010) Intra-cerebral injection of neuromyelitis optica immunoglobulin g and 
human complement produces neuromyelitis optica lesions in mice. Brain 
 
Khorooshi R. et al., 2015 Hypersensitivity response in the central nervous 
system. Front Immunol 
 
  
92 
 
Fletcher et al. 20102 The anatomical and cellular basis of immune surveillance 
in the central nervous system. Nature Reviews Immunology 
 
Potelle S. et., 2014 Golgi post-translational modifications and associated 
diseases, Journal of Inherited Metabolic Disease 
